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1. HUMAN REPRODUCTIVE BEHAVIOR MOTIVATION AND PHENOTYPE  
DEFINITION 
1.1 Phenotype Motivation 
 
Human reproductive behavior – measured by age at first birth (AFB) and number of children 
ever born (NEB) – is a core topic of research across the medical, social and biological 
sciences.1 Two central indicators are the tempo of childbearing of age at first birth (AFB) and 
the quantum or number of children ever born (NEB). NEB is also often referred to in 
biological research as life-time reproductive success,2 number of offspring3 or as ‘fitness’ in 
evolutionary studies, which is the function of the number of children of a person in relation to 
the number of children of peers of the same birth cohort.4,5 Due to improvements in hygiene 
and the reduction in prenatal, infant and child mortality in industrialized societies, NEB has 
emerged as the gold standard to measure lifetime reproductive success indicating biological 
fitness.5 
 
AFB and NEB are complex phenotypes related not only to biological fecundity, but also 
behavioral in that they are driven by the reproductive choice of individuals and their partners, 
and shaped by the social, cultural, economic and historical environment. Genetic factors 
influence the first two factors of biological fecundity and choice, with the social and 
historical environment filtering the types of behavior that are possible (e.g., via contraceptive 
legislation, social norms).  
 
Although interrelated, AFB and NEB, but also childlessness, are distinct phenotypes. Late 
AFB, low NEB or remaining childless is not only due to ‘involuntary’ infertility or factors 
outside of the individual’s control (e.g., inability to find a partner), but also ‘voluntary’ 
choices to remain ‘childfree’.6 In the past four decades there has been a rapid postponement 
by around 4-5 years in the AFB to advanced ages in many industrialized societies7 and a 
growth in childlessness, with around 20% of women born from 1965-69 in Southern and 
Western European countries having no children.8 The biological ability to conceive a child 
starts to steeply decline for some women as of age 25, with almost 50% of women sterile by 
the age of 40.9 Birth postponement and a lower number of children has been largely 
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attributed to social, economic and cultural environmental factors (i.e., individual and partner 
characteristics, socioeconomic status).7,10 Not surprisingly, this delay has led to an 
unprecedented growth in infertility (i.e., involuntary childlessness), which impacts between 
10-15% of couples in Western countries, with men and women affected equally.8 An 
estimated 48 million couples worldwide are infertile,11 with a large part of subfertility, 
particularly in men, remaining unexplained.12 Although therapeutic options for infertility in 
the form of Assisted Reproductive Technology (ART) are available, they are highly 
ineffective at later ages and older mothers have considerably more problems during gestation 
and delivery, also associated with low birth weight and preterm delivery.13–15  Recent studies 
have also linked advanced maternal age to a higher risk of schizophrenia in offspring.16 
 
Childless individuals (and those with a low NEB) are a heterogeneous group consisting of the 
involuntary childless (e.g., infertility, sterility) and voluntarily childless or ‘childfree’ (e.g., 
out of choice). Although primarily related to biological fecundity, involuntary childlessness 
may also be due to circumstantial socio-environmental reasons outside of the individual’s 
control, including a lack of ability to find a stable partner,17  divorce and lack of housing, 
employment or material resources to start a family.18 Those who are voluntarily childless are 
generally considered to have made an active choice or to be endowed with an underlying 
preference19 or personality traits that pull individuals towards or away from parenthood.20 It 
is difficult to disentangle the voluntary from the involuntary, however, since fertility 
intentions can be adjusted in relation to circumstances21 and these modifications are age-
related.22 
 
A better understanding of the genetic architecture of human reproductive behavior and its 
relation to the environment would enable the discovery of predictors of infertility, which 
would in turn greatly improve family planning but also reduce costly and invasive ART 
treatments. Examination of AFB and NEB may also produce a better understanding of the 
biology of human reproduction, which in turn may give insight into fundamental biological 
mechanisms and could have ramifications for the study of many health outcomes, especially 
the etiology of diseases related to the reproductive tract. Furthermore, it is important to 
understand whether and which proportion of these traits are driven by genetic, behavioral and 
environmental factors.  Relatively little is known about the relationship between indicators of 
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women’s reproductive lifespan (menarche, menopause) and reproductive success. A smaller 
and recent study has produced some evidence of the link between age at first sexual 
intercourse (AFS) with AFB and NEB, with a focus on puberty and development.23  
 
By systematically investigating the relationship with genetic variants for a multitude of 
phenotypes related to human reproduction we can establish to what extent diseases related to 
the reproductive tract play a role in human reproduction and vice versa, and begin to chart the 
complex biological and related mechanisms that drive human reproduction. It is therefore 
crucial to examine not only genetic determinants of more biologically proximate phenotypes 
(e.g. age at menarche, endometriosis, PCOS) but also human reproductive behavior and 
success. AFB and NEB represent more accurate and concrete measures of observed 
reproductive success in comparison with proxies which capture the reproductive life span 
(e.g., age at menarche, menopause) or infertility measures (e.g., endometriosis, PCOS).  
 
To our knowledge, the current study is the largest meta-GWAS effort on human reproductive 
behavior, which we launched in early 2012. As mentioned previously, a recently published 
smaller and related study of cohorts also involved in our study focused on age at first sex 
(AFS), also linking it to AFB and NEB (among other traits).23 The AFS study examined how 
individual variation in pubertal timing and personality characteristics related to high risk-
taking and low neuroticism related to reproductive activity and success with AFS measures, 
measures integrated into our examination of genetic correlations (see Supplementary Note, 
section 7).  
 
Several studies have shown promising results for fertility-related outcomes related to both 
infertility and the reproductive life span. Previous research has uncovered a genetic 
component to reproduction with over 70 genome-wide association studies (GWAS) published 
for 32 traits and diseases associated with reproduction (for a review see ref. 24). This includes 
identification of genes such as those related to age at menarche25,26,27, menopause28–32, 
endometriosis33–36 and polycystic ovary syndrome37. This study is the first step towards 
understanding the pathways between genes and the complex relationship between 
reproduction and other phenotypes and the environment.  
 
7 
 
1.2 Evolutionary causes of genetic variance in fertility 
Given the diminishing child mortality rate in contemporary societies, evolutionary biologists 
have used NEB as a proxy for fitness.2,5,38 Additive genetic variance in fitness implies natural 
selection within populations: alleles that lead to higher reproductive success will have a 
higher frequency in future generations.39 Researchers have until now arguably given less 
attention to NEB than it deserves,1 perhaps due to a frequent erroneous interpretation of 
Fisher’s40 Fundamental Theorem of Natural Selection. The theorem states that the increase in 
population mean fitness ascribable to changing allele frequencies is equal to the additive 
genetic variance in fitness. It has often been misinterpreted, however, to mean that the 
additive genetic variance in fitness itself should always be close to zero. A close reading of 
the text shows that Fisher actually argued that fitness is moderately heritable in human 
populations. The misinterpretation of Fisher’s theorem is likely repeated so often due to its 
intuitive appeal. Naively, it may seem that genes that reduce fitness should have been less 
frequently passed on, leading to the elimination of genetic variability in traits such as 
fertility.40,41 Nevertheless, we find that fitness traits such as NEB and AFB have significant 
narrow-sense heritabilities – yet these traits are still not as heritable as morphological traits 
such as height.38,42–44 Several reasons have been put forward to explain the persistent genetic 
variance in fertility. One argument is that new mutations suffice to restore any genetic 
variance lost to selection.45 For the current study design, additional aspects to consider are 
sexual antagonistic genetic effects, non-additive genetic effects, environment and gene-
environment interaction. As discussed in more detail in the Supplementary Note (Section 5), 
the current GWAS was conducted separately for both sexes, with a detailed examination 
explored within that section.   
1.3 Additive genetic variation in fertility 
Several twin and family studies provide evidence for a genetic component underlying both 
the tempo (AFB) and quantum (NEB) of human fertility.1,3 Heritability – the proportion of 
the variance in a trait explained by genetic variance – is typically assessed by a comparison 
of the phenotypic correlations of family members of different genetic relatedness (for 
example genetically identical or monozygotic and genetically fraternal dizygotic twins). The 
genetic component is the extent to which genetically identical twins are more similar in their 
fertility behavior. As summarized in Fig. S1.1, heritability estimates for AFB (for women) 
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are around 0.25 and for NEB ranging from 0.15 to 0.45.1 A recent meta-analysis of all twin 
studies conducted until 201244 shows average heritability of 0.45 (SE = 0.027, N = 50,265) 
among 64 reproductive disease traits of women and of 0.36 (SE= 0.054, N = 9,376) among 
25 reproductive disease traits of men. These mainly pertain to diseases of the genitourinary 
system, endocrine, nutritional and metabolic diseases, and only few directly pertain to 
pregnancy, childbirth and the puerperium.  
 
With the advent of molecular genetic data and complementary analytical tools,46 it has 
become feasible to go beyond twin models to produce heritability estimates to apply the same 
logic to unrelated individuals based on the genetic relatedness matrix across all individuals 
estimated from common SNPs from the whole genome.47,48 A recent study combined data 
from the Lifelines Cohort Study and the TwinsUK to estimate this so called SNP-based 
heritability as the lower bound of narrow sense heritability.38 Results show that 10% of the 
variance in NEB and 15% of the variance in AFB are associated with common additive 
genetic variance. Given that SNP-based heritability is estimated from the same genomic 
information as utilized in GWAS studies, these results suggest that we should be able to find 
genetic variants associated with human fertility when conducting GWAS meta-analyses of 
sufficient sample size. 
 
1.4 Dominant genetic variation in fertility  
GWAS typically assume additive genetic effects. Dominant models, however, are in principle 
also applicable.49 Dominant genetic effects and overdominance (heterozygote advantage) are 
mechanisms which potentially maintain non-additive genetic variation in fertility and other 
fitness related outcomes.40 Dominant genetic effects result if the conditional phenotypic mean 
of the heterozygote is not exactly intermediate between those of the homozygotes. 
Overdominance refers to the special case of the heterozygote possessing a fitness advantage 
over both homozygotes. At the equilibrium under selection, overdominance leads to an 
absence of additive genetic variance. Any deviation from strict additivity within a locus, 
however, should lead to dominance variance that is in principle detectable.45 
 
9 
 
Previous studies approaching the genetic architecture of human fertility almost exclusively 
relied on twin designs.1 Dominant genetic effects are detectable in twin studies if the 
correlation in a trait among identical twins exceeds twice the correlation of fraternal twins. 
Correlations amongst family members, however, can by inflated by shared environmental 
factors and therefore hide dominant effects – a potential reason why previous twin studies did 
not find effects.49 
 
Recently, Zhu and colleagues49 developed a method to estimate dominant genetic effects 
based on the genetic relatedness of unrelated individuals. This is a complementary approach 
to the established GREML analysis, which estimates additive genetic effects on traits. In the 
article of Zhu and colleagues, they quantify dominant relative to additive variance 
components for 79 quantitative traits and find little evidence for dominant effects. We 
applied the GREML model to investigate additive genetic effects on NEB and AFB in 
combined cohorts of women from the TwinsUK and the Lifelines study in the Netherlands.38 
On a slightly larger sample – with a relaxed relatedness cut-off of 0.0550 and the exclusion of 
women younger than 45 for AFB – we replicated previous findings with a SNP-heritability of 
0.09 for NEB and 0.17 for AFB. However, we find no evidence for dominant genetic effects 𝛿"#$%  for either NEB (0.1x10-06, SE  0.07, P=0.45) nor AFB (0.02, SE=0.08, P=0.43, see 
Supplementary Table 28 for results). We can therefore conclude that due to this lack of 
evidence of dominant genetic effects, it is not problematic that we have excluded dominant 
models in our GWAS.  
 
1.5 Environmental variations in fertility 
Social scientists, such as demographers and sociologists, have attributed later ages of first 
birth, lower NEB and growing levels of childlessness in many industrialized societies almost 
exclusively to socio-environmental factors.7,10 The underlying socio-environmental forces 
shaping fertility can be divided into four main factors. First, the introduction of efficient and 
reliable contraceptives in the early 1960s revolutionized human reproductive behavior, 
namely the ability to control the timing and number of children.7 The diffusion of the pill in 
the late 1960s in the United States resulted in an almost immediate postponement in the age 
of first marriage for college-educated women.51 Contraception allowed women and couples 
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to avoid pregnancy and delay entry into parenthood. Contraceptives were generally widely 
introduced across Western and Northern Europe, Australia and North America in the late 
1960s, which is where the majority of cohorts are situated in the current study.  
 Second, there is a well-documented association between female education and later 
AFB.52 Early research demonstrated a strong inverse relationship between education and 
fertility, with women’s increased participation in higher college and University degrees 
resulting in a significant shift to later AFB.53–55 A central argument driving childbearing 
delay was the difficulty to balance student and mother (parent) roles, but also women’s 
opportunity costs in terms of wages and career progression that they forego when having 
children early.56–58 A third factor, which is interdependent with educational level, is women’s 
labor force participation and attachment. Research has demonstrated an incompatibility of 
early AFB and high NEB with paid labor force participation,59 largely due to work-family 
conflict7 and the high motherhood ‘wage penalty’. In fact, the postponement of AFB results 
in substantial increases in earnings, particularly for higher-educated women.60,61 It is 
estimated that there is a 7% motherhood wage penalty per child, with a year delay of entry 
into motherhood increasing career earnings by 9%.61 
 A fourth factor is the Second Demographic Transition, which encompasses cultural 
and ideational changes surrounding the preferences for and role of children, which is coupled 
with a shift to more individualistic desires for personal development.62,63 Since infant 
mortality rates have fallen sharply in modern societies, extra births are not required for 
insurance against death and children no longer provide the economic support and labor to 
support parents that they once did, which dramatically changes preferences and the need to 
have children.64,65 Multiple national institutional factors have also been shown as related to 
the delay of AFB and the decrease in NEB. This includes changes in the educational systems, 
labor market regulations, gender equity,66 but also economic uncertainty,67 the housing 
market,68 influence by friendship networks,69 family networks and social capital,70 and 
changes in partnering and mating practices.71 The empirical relationship of these factors – 
namely birth cohort and educational level – with genetic risk scores of AFB and NEB is 
elaborated upon in section 10.  
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1.6 Phenotype definition 
The current study measures human reproductive choice by the two phenotypes of: age at first 
birth (AFB) and number of children ever born (NEB). AFB is the self-reported age when 
subjects had their first child. In most cohorts this was asked directly (e.g. “How old were you 
when you had your first child?”). Alternatively, it could also be calculated based on several 
survey questions (such as the date of birth of the subject and date of birth of the first child). 
Supplementary Table 2 describes in detail the exact question asked for each cohort and if 
applicable, whether and how it varies in the way it was asked to men and women. Often these 
questions were part of a medical questionnaire about women’s reproductive health. In a large 
number of cohorts, this means that only women were asked this question. For this reason, the 
sample size for AFB for women is considerably larger than for men. Note that only people 
who have had at least one child (parous) are eligible to be included for the analysis of this 
phenotype. 
 
Number of children ever born (NEB) was the self-reported number of children. This 
phenotype was either asked directly (e.g. “How many children do you have?” or “How many 
natural (biological) children have you ever had, that is, all children who were born alive?”, 
or “How many children have you had - not counting any step, adopted, or foster children, or 
any who were stillborn?”) or it was calculated based on several survey questions (such as 
pregnancy histories and outcomes, number of deliveries). In most cases it was possible to 
distinguish between biological (live born or stillborn) and adopted or step-children. When it 
was possible to distinguish between cases, we used the number of live born biological 
children. We included cases for NEB if they finished their reproductive career (aged at least 
45 for women and 55 for men at time of study) and were thus unlikely to have future 
biological children. 
 
1.7 Instructions for contributing cohorts 
The instructions given to cohorts who agreed to participate in our study is described in detail 
in the original Analysis Plan that was posted on the Open Science Framework preregistration 
site, described in detail in Supplementary Note Section 2.1 and uploaded December 9, 2013 
at: https://osf.io/53tea/.  For ease of analysis, we advised that AFB should be treated as a 
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continuous measure. When possible, we asked analysts to use the more direct question: How 
old were you when you had your first child? Another variant of this question is: What is the 
date of birth of your first child? In the case of the latter, we advised them to create the AFB 
variable by subtracting the date of birth of the first child from the date of birth of the subject. 
 
Analysts then normalized the raw measure of the age at first birth for sex/ birth cohort 
specific means and standard deviations. In other words, we asked them to compute a mean 
and standard deviation separately for men and women by birth cohort category (generally 
ten-year intervals) and then subtract the mean value for that group from the respondent’s 
value. They should then divide the result by the standard deviation.  This was used as the 
final AFB variable measured in sex/cohort specific Z-score and is our regressand. 
 
Analysts were asked to include birth year of the respondent (represented by birth year – 
1900), its square and cubic to control for non-linear birth cohort effects. Combined analyses 
that included both men and women also needed to include interactions of birth year and its 
polynomials with sex. Some cohorts only used birth year and not its polynomials because of 
multi-collinearity issues/convergence of the GWA analysis.  
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2. PRIMARY GWAS OF HUMAN REPRODUCTIVE BEHAVIOR 
2.1 Overview of human reproductive behavior analyses 
The genome-wide association study (GWAS) of human reproductive behavior is based on the 
summary statistics that were uploaded to a central server by cohort-level analysts. As 
outlined in more detail in Section 1 of the Supplementary Note, our analysis includes the two 
phenotypes of age at first birth (AFB) and number of children ever born (NEB), with analysts 
producing results for women, men and combined analyses of both sexes, also including birth 
cohort as a covariate. The summary statistics were then subsequently quality-controlled and 
meta-analyzed by two separate independent centers at the University of Oxford and Erasmus 
University Rotterdam.  
 
We follow the QC protocol of the GIANT consortium’s recent study of human height72 and 
employed the software packages QCGWAS73 and EasyQC74, which allowed us to harmonize 
the files and identify possible sources of errors in association results. This procedure entailed 
that diagnostic graphs and statistics were generated for each set of GWAS results (i.e., for 
each file). In the case where apparent errors could not be amended by stringent QC, cohorts 
were excluded from the meta-analysis (see the bottom of Supplementary Table 1 for a list of 
excluded cohorts).  
 
The lead PI of each cohort confirmed that the results on these analyses were approved by the 
local Research Ethics Committee and/or the relevant Institutional Review Board. All 
participants fell under the written informed consent protocol of each participating study. The 
entire project was also approved by the local Research Ethics Committee of the PI.  
 
We first circulated three documents to interested cohorts at the end of April 2012, which 
included: (a) Rationale for a GWAS of Fertility Behavior, (b) GWAS Fertility Behavior 
Analysis Plan; and, (c) Collaboration Agreement for Fertility GWAS Meta-analyses. This 
was after a meeting and approval from the REPROGEN working group of the CHARGE 
consortium on Dec. 9, 2011 that we were not competing with or unduly replicating existing 
efforts. Preliminary results were presented at various CHARGE meetings between the years 
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of 2012-2015. This study was initially set up as a two-stage GWAS with a large discovery 
and smaller replication phase. Due to an increasing influx of new data, we opened the 
participation to cohorts that had genome-wide data, but also to cohorts that had Metabochip 
data. We also included a list of 15 independent SNPs with P<10-06 for cohorts that did not 
have genome-wide data available but could perform de-novo replication on a limited number 
of SNPs. Agreements at a later stage included data from RPGEH (Kaiser Permanente 
Research Program on Genes, Environment, and Health, REPEGH/GERA), N(AFB 
women)=31,898, N(NEB women)=39,576), deCODE (N(AFB pooled)=60,602, N(NEB 
pooled)=65,228), and UK Biobank (N(AFB women)=40,082, N(NEB pooled)=88,094). 
Given the resulting well-powered total sample size of N≈250k for AFB and N≈340k for NEB, 
we chose to merge the discovery and replication cohorts into a single large discovery phase, 
as in other recent well-powered GWAS efforts.72,75,76 We also opted to include only cohorts 
with genome-wide data in the meta-analysis, leaving the remaining cohorts that performed 
de-novo replication for follow-up analysis.  
 
2.2 Participating Cohorts  
A total of 62 cohorts contributed to this study. Cohorts with acceptable measures of AFB 
and/or NEB were eligible to participate. Some measured one or both of the phenotypes, and 
there was also variation by whether the question was asked to women and/or also men. 
Supplementary Table 1 provides an overview of the study-specific details of all analyses 
conducted for the traits of interest. Cohorts of unrelated individuals uploaded separate results 
for men and women. In addition to sex-specific association results, family-based cohorts 
uploaded pooled results. As described in the Supplementary Note (Section 1), particularly 
AFB is less frequently asked of men. The total number of association-result files per trait is 
as follows. We have 28 files for AFB men, 57 for AFB women, 72 for AFB pooled, 50 for 
NEB men, 67 for NEB women, and 102 for NEB pooled. 
 
As Supplementary Table 1 shows, most cohorts were included in the meta-analysis (i.e., 62 
cohorts are included, constituting 26 files for AFB men, 50 for AFB women, 64 for AFB 
pooled, 47 for NEB men, 60 for NEB women, and 91 for NEB pooled) and some only in the 
follow-up analyses (9 cohorts, constituting 2 files for AFB men, 5 for AFB women, 6 for 
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AFB pooled, 3 for NEB men, 5 for NEB women, and 9 for NEB pooled). We had to exclude 
the association results of two cohorts – ABCFS (AFB women, N=410, NEB women, N=410) 
and Longenity (AFB women, N=285; NEB women, N=352) –  from the meta- and follow-up 
analyses due to unresolvable issues with the cohort’s association results that came up in the 
quality control procedures. For more details regarding the reasons for exclusion, see SI 
Section 2.6. 
 
2.3 Genotyping and Imputation 
Supplementary Table 1 gives an overview of the study-specific details on pre-imputation 
quality control filters applied to the genotype data, subject-level exclusion criteria, imputation 
software used, and the reference sample for imputation. Due to the fact that we started our 
study in 2012 before 1000G imputation, our analysis plan recommended using resulted 
imputed using the HapMap 2 CEU (r22.b36) reference sample.77 
 
2.4 Association analyses 
Cohorts were asked to only include participants of European ancestry, with no missing values 
on all relevant covariates (sex, birth year, and cohort specific covariates), who were 
successfully genotyped genome-wide (e.g., genotyping rate greater than 95%), and who 
passed cohort-specific quality controls (e.g., no genetic outliers). 
 
Cohorts used the fully imputed set of HapMap Phase 2 autosomal SNPs, and estimated an 
additive linear model, including top principal components to control for population 
stratification and cohort specific covariates if appropriate. They were specifically instructed 
to control for population stratification for ancestry principal components with reference to 
Price et al. (2006).78 In addition, cohorts were requested to include the birth year of the 
respondent (represented by birth year – 1900), its square and cubic to control for non-linear 
birth cohort effects. Analyses pooling data across sexes also needed to include interactions of 
birth year and its polynomials with sex. Some cohorts only used birth year and not its 
polynomials because of multi-collinearity issues/convergence of the GWA analysis. 
Omission of these nonlinear birth year effects is unlikely to lead to biased inferences, since 
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genotypes are not usually considered as truly associated with birth year. However, inferences 
might be less accurate (i.e., have larger standard errors), since omission of nonlinear birth 
year effects can lead to larger residual variation. 
2.5 Quality Control  
In this section, we summarize the main steps and diagnostic tests of the Quality Control (QC) 
procedure. The quality control was conducted in two separate independent analysis centers 
(Oxford/Groningen and Rotterdam). Once data were submitted, each study was 
independently subjected to quality control in the two analyses centers according to standard 
protocols. We followed the QC protocol of the GIANT consortium’s recent study of human 
height72 and the SSGAC’s study of educational attainment.76,79 
 
Since this study began, QC procedures have become more stringent. Recently, a 
comprehensive set of guidelines for GWAS QC was released.7 For the cohorts initially 
included in the study a first round of QC was performed using the R package QCGWAS73. 
We updated the QC protocol based on the GIANT consortium’s and SSGAC’s protocols. The 
updated QC protocol was applied to all cohorts using the R package EasyQC.74 Findings of 
the first round of QC were used as a starting point for the updated QC. 
 
In the QC procedure, diagnostic graphs and statistics were generated for each set of GWAS 
results (i.e., for each result file uploaded by the cohort analysts). Most errors (e.g., coded 
allele reported as other allele and vice versa) could be easily addressed. When apparent errors 
could not be amended by combining stringent QC with file-specific inspections and 
corrections, cohorts were excluded from the meta-analysis. For details on cohort inclusion 
and exclusion, see Supplementary Table 1. 
 
Filters 
We harmonized base pair positions of the markers across files using NCBI build 37. For each 
result file, a given marker was excluded in case: 
1. The combination of chromosome and base-pair position could not be uniquely linked to the HapMap Phase II CEU panel.  
2. The marker had missing or incorrect values.  Specifically, 
a. the effect allele and other allele were missing, 
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b. the association p-value was missing or outside the unit interval, 
c. the effect estimate was missing or reported to have infinite magnitude, 
d. the standard error (SE) of the effect estimate was missing, negative, or infinite, 
e. the allele frequency was missing or outside the unit interval, 
f. the sample size was not reported, or zero or below, 
g. the reported callrate was outside unit interval, 
h. the reported imputation quality was negative, and 
i. the reported imputed dummy was not binary. 
3. The marker was not a SNP, not biallelic, non-autosomal, and/or monomorphic. 
4. The sample size was below 30.  
This filter is to guard against spurious associations due to overfitting of the model. 
5. The minor allele count was 6 or below.  
This filter is to guard against spurious associations with low-frequency SNPs in small samples. The risk of spurious 
associations has shown to be particularly high for SNPs that are extremely rare7.  
6. Minor allele frequency (MAF) was below 1%.  
For all the cohorts, we dropped SNPs with a MAF below 1%. For small cohorts we applied more stringent filters based 
on diagnostic tests and figures. 
7. The SE of the effect estimate was greater than 100 𝑁. 
Based on the approximation to the expected standard error by Winkler et al.7, we calculated that an SE greater than 100 𝑁 is at least 40% greater than the expected SE of the estimated effect of a SNP with a MAF of 1% for a trait with 
standard deviation of 10. Since in our analyses we only consider SNPs with MAF≥1% and traits with a standard deviation 
below 10, an effect estimate with an SE greater than 100 𝑁 can be considered to be unreasonably large.  
8. The R2 of the marker with respect to the phenotype was greater than 10%. 
We excluded SNPs for which the estimated R2 was greater than 10% (Supplementary Information in Rietveld et al.79) 
because such an R2 would defy all upper bounds on reasonable effect sizes of SNPs. 
9. The marker was imputed while imputation quality was missing. 
10. The marker was imputed while imputation quality was below 0.4.  
For all the cohorts, we dropped imputed SNPs with an imputation quality below 0.4. For several cohorts we apply more 
stringent filters based on diagnostic tests and figures. 
11. The callrate was below 95%.  
12. The SNP was genotyped and not in Hardy-Weinberg Equilibrium (HWE). 
We excluded genotyped SNPs if they fail the HWE chi-squared test. Violation of HWE will lead to lower chi-squared p-
values as sample size increase, the threshold is therefore sample-size dependent. We applied an HWE p-value threshold 
of 10-03 in case N < 1,000, 10-04 in case 1,000 ≤ N < 2,000, 10-05 in case 2,000≤N<10,000, and no filter in case N≥ 
10,000). 
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Diagnostic checks 
For the SNPs remaining after applying the filters of steps 1 – 12, we generated five key 
diagnostic graphs: 
1. Allele frequency (AF) plots. – to identify errors in allele frequencies and strand orientations. 
The AF plot shows the expected AF (based on the HapMap II CEU2 reference panel or the 
1000 Genomes Phase 1 European panel in case of 1000 genomes imputed data) versus the 
reported AF. 
2. Reported P-values versus P-values of the Z-scores (PZ) plots – to assess the consistency of the reported P-values with 
respect to those implied by the effect estimates and the corresponding standard errors. 
3. Quantile-Quantile (QQ) plots – to check for evidence of unaccounted population stratification. 
4. Reported Standard Error versus Expected Standard Error (SE) plots – to assess whether the reported standard errors 
behave in line with the approximation of the expected standard errors provided by Winkler et al.74 , implemented as a QC 
step by Okbay et al.80  
 
These diagnostic plots were examined by two independent analysts. If problems were 
detected which could not be resolved by more stringent thresholds, we applied the following 
ad hoc filters (descending order in terms of frequency used).  
 
1. MAF filters more stringent than the generic MAF filter (e.g., 5% instead of 1%). 
2. Imputation quality filters more stringent than the generic filter (e.g., 0.8 instead of 0.4). 
3. Filter on the absolute difference between expected (based on the HapMap II CEU2 reference panel or the 1000 Genomes 
Phase 1 European panel in case of 1000 genomes imputed data) and reported allele frequencies. This filter helps to remove 
clear outliers in the AF-plots (e.g., strand-ambiguous SNPs that are likely to have been reverse-coded). 
4. Filter on the absolute difference between the reported log(P-value) and the log(P-value) derived from the report Z-score. This 
filter helps to remove clear outliers in the PZ-plots. Such outliers can arise when software such as SNPTEST13 switches to 
another estimation method, for reasons such as poor convergence of the estimates. 
 
For a list of the filters used per cohort, per association file, see Supplementary Table 27, 
which reports the total number of markers prior and post-QC when applying the described 
generic and specific filters, for each set of association results. 
 
The AF plots for ABCFS (N=410 for AFB and NEB) shows a strong anti-diagonal that 
persists when considering only genotyped markers, implying that reverse-coded SNPs are 
likely to have been used for imputation, thereby yielding poorly imputed SNPs. 
Consequently, we exclude the ABCFS result files from the meta-analyses. In addition, for 
Longenity (N=285 for AFB and N=352 for NEB) many SNPs have far greater standard errors 
19 
 
for the effect estimates than expected, as well as callrates substantially below 95%. When 
applying QC to Longenity, only several hundreds of SNPs are left after QC. Consequently, 
we also exclude Longenity results from the meta-analyses. 
 
2.6 Meta analyses 
Cohort association results (after applying the QC filters) were combined using sample-size 
weighted meta-analysis, implemented in METAL.81 Sample-size weighting is based on Z-
scores and can account for different phenotypic measurements among cohorts.82 The two QC 
centers agreed in using sample-size weighting to allow cohorts to introduce study-specific 
covariates in their cohort-level analysis.  Only SNPs that were observed in at least 50% of the 
participants for a given phenotype-sex combination were passed to the meta-analysis. SNPs 
were considered genome-wide significant at P-values smaller than 5×10-08 (α of 5%, 
Bonferroni-corrected for a million tests. The meta-analyses were carried out by two 
independent analysts. Comparisons were made to ensure concordance of the identified 
signals between the two independent analysts. The PLINK clumping function83 was used to 
identify the most significant SNPs in associated regions (termed “lead SNPs”). 
 
The total sample size of the meta-analysis is N=251,151 for AFB pooled and N=343,072 for 
NEB pooled. Although considered to be separate from our main pooled results, we also 
performed separate meta-analyses for 
 
• AFB women (N=189,656), 
• AFB men (N=48,408), 
• NEB women ( =225,230), 
• NEB men (N=103,909) 
 
The sex-specific results are discussed in more detail in Supplementary Note, Section 5. To 
understand the magnitude of the estimated effects, we used an approximation method to 
compute unstandardized regression coefficients based on the Z-scores of METAL output 
obtained by sample-size-weighted meta-analysis, allele frequency and phenotype standard 
deviation. Further details of the approximation procedure are available in the Supplementary 
Information of Rietveld et al.79 
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Figure S2.1.1. to Figure S2.13.2 contains the forest plots and regional association plots of all 
genome-wide significant SNPs, the latter created by LocusZoom plots.84 The forest plots 
provide a visualization of the effect size estimates for each cohort and the summary meta-
analysis (red rectangle) in addition to the 95% confidence intervals. As would be expected, 
small cohorts have larger confidence intervals. LocusZoom plots provide a graphic depiction 
of the local association results and include information about the locus, the location and 
orientation of the genes it includes, LD coefficients and the local estimates of recombination 
rates. 
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3. BIVARIATE AND CONDITIONAL ANALYSIS OF THE TWO FERTILITY-
RELATED TRAITS 
 
As joint analysis of correlated traits may boost power for mapping functional loci, we applied 
a recently developed multi-trait analysis method85 to test the association between each variant 
and the two correlated traits AFB and NEB simultaneously using multivariate analysis of 
variance (MANOVA). The analysis was performed based on the genome-wide meta-analysis 
summary statistics of each single trait. The joint analysis did not reveal additional genome-
wide significant loci (𝜆=0.995), however, such bivariate analysis, accounting for the 
correlation between the two phenotypes, improved the strength of two signals on 
chromosomes 1 and 5, indicating possible pleiotropic architecture between the AFB and NEB 
(Supplementary Figure 30).  
 
The analysis also provides a conditional association test of the genetic effect of each variant 
on AFB including NEB as a covariate, and that on NEB including AFB as a covariate. The 
conditional analysis also did not reveal additional genome-wide significant loci 
(Supplementary Figure 31). Nevertheless, adjusting for NEB eliminated the three genome-
wide significant loci on chromosomes 1, 2 and 6 for AFB, and adjusting for AFB eliminated 
the two genome-wide significant loci on chromosomes 1 and 14 for NEB, which may 
indicate underlying pleiotropic effects on both traits across these loci. 
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4. TESTING FOR POPULATION STRATIFICATION 
 
Population stratification can severely bias GWAS estimates for causal variants and lead to 
false positives. This can occur if a particular variant of a SNP is more common in a particular 
subpopulation and if there are mean differences in the phenotype of interest between 
subpopulations due to factors that do not involve that SNP.  As described in Supplementary 
Note Section 2, all cohorts in the GWAS  of AFB and NEB included the top principal 
components78 in their analyses to account for population stratification. Even despite this 
inclusion, residual stratification could still remain and affect the results.  
 
To test the extent of this problem, we used two methods to assess if our GWAS results for 
AFB and NEB exhibit signs of population stratification. First, we used the LD Score intercept 
method described in Bulik-Sullivan et al..86 Second, we conduct a series of individual and 
within-family (WF) regressions using polygenic scores (PGS) as predictors87–89 on a dataset 
of DZ twins (STR and TwinsUK).  Within-family regressions are based on family differences 
in PGS for AFB and NEB and are therefore are not affected by population stratification. We 
compare the coefficients of individual and WF regression using different p-value thresholds 
for the construction of PGS. Polygenic scores are based on independent results (i.e. meta-
analysis results excluding STR and TwinsUK). Additional information on how we computed 
our PGS are available in Section 7 of the Supplementary Note.  
 
4.1 LD Score Intercept Test  
The LD Score intercept test uses GWAS summary statistics for all measured SNPs. LD Score 
regression is a method that can disentangle inflation in the chi-square statistics that is due to a 
true polygenic signal throughout the genome from inflation that is due to confounding biases 
such as cryptic relatedness and population stratification. The inflation due to a true polygenic 
signal impacts the slope of the LD regression, whereas inflation due to population 
stratification and other confounding biases affects the intercept of the regression. 
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We used the LDSC software86,90 to estimate the intercepts in LD Score regressions with the 
summary statistics of our GWAS of: (i) AFB (pooled sample), (ii) NEB (pooled sample), (iii) 
AFB (women), (iv) AFB (men), (v) NEB (women), and, (vi) NEB (men). We estimated a 
separate LD Score regression for each of the phenotypes using the summary statistics from 
the meta-analyses based on all available data.  
 
For each phenotype, we used the “eur_w_ld_chr/” files of LD Scores computed by Finucane 
et al.91 available on https://github.com/bulik/ldsc/wiki/Genetic-Correlation. These LD Scores 
were computed with genotypes from the European-ancestry samples in the 1000 Genomes 
Project using only HapMap3 SNPs. Only HapMap3 SNPs with MAF > 0.01 were included in 
the LD Score regression.  
 
Because genomic control (GC) will tend to bias the intercept of the LD Score regression 
downward, we did not apply GC to the summary statistics we used to estimate the LD Score 
regression. Furthermore, we excluded the deCODE cohort from the data for the estimation of 
the LD Score intercept for AFB and NEB, since the cohort-level regression estimates for 
deCODE did not directly correct for the high level of relatedness in the sample (their standard 
procedure is to apply GC). Our intercept estimates from the LD Score regressions are thus 
unbiased measures of the amount of stratification there is in the data (excluding deCODE) 
that we used for the GWAS of each phenotype.  
 
Supplementary Note Figures 4.1 and 4.2 show LD Score regression plots based on the 
summary statistics from the GWAS of AFB, and NEB. For AFB, we estimated a LD Score 
intercept of 1.0216 (SE=0.008) and for NEB, 1.009 (SE = 0.006). In all six cases, the 
intercept estimates are not significantly different from 1. By comparison, the mean 𝜒2 
statistics for all the SNPs in the LD Score regressions are 1.239 for AFB and 1.141 for NEB. 
Under the null hypothesis that there is no confounding bias and that the SNPs have no causal 
effects on the phenotypes, the mean 𝜒2 statistics would be one, thus mean 𝜒2 statistics greater 
than one indicate that some SNPs are associated with the phenotypes. These estimates imply 
that about 9% of the observed inflation in the mean 𝜒2 statistics for AFB and  about 6% of the 
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inflation for NEB is accounted for by confounding bias (due to relatedness, or other 
confounds) rather than a polygenic signal.  
 
As described in Section 2 of the Supplementary Information, we applied the standard single 
GC correction to produce our main estimates.  Once a single GC is applied, the LD score 
regression estimates indicate negligible confounding bias due to population stratification. The 
LD score intercept for AFB is 0.9618 (SE= 0.0077) and for NEB 0.9763 (SE=0.0068). We 
can therefore conclude that the amount of inflation in our final results due to confounding 
bias is likely to be negligible.   
 
4.2 Statistical Significance of the Polygenic Scores in a WF regression 
To test the robustness of our all-SNP polygenic scores calculated with a set of SNPs meeting 
several different threshold P-values (5e-08, 5e-07,5e-06, 5e-05, 5e-04, 5e-03, 5e-02, 5e-01, 
all SNPs), we estimated WF regressions of AFB and NEB on each polygenic score in 
samples that are independent from those used to construct the scores. For each WF 
regression, we also compared the estimated coefficient on the polygenic score to the 
corresponding coefficient from individual-level regression.  
 
For both the individual-level and WF regression, we standardized NEB and AFB on 
birthyear, birthyear squared, birthyear cubic, sex and the first 10 PCAsa. Our regressions are 
based on 7,944 twin couples for AFB and 9,220 twin couples for NEB. Supplementary Note 
Figures 4.1, 4.2 and Supplementary Tables 30, 31 report the results.  
 
The regression analyses show that WF regression coefficients for both AFB and NEB are 
statistically different from zero when the p-value threshold is sufficiently far from zero. 
When including all SNPs, both coefficients for AFB and NEB are larger than zero, 
confirming that the GWAS analyses uncovered true polygenic signals. Overall, these results 
indicate a minimum effect of population stratification and the existence of polygenic signals.  
                                                
a Details on the construction of polygenic scores is available in section 6 of the Supplementary Note.  
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5. SEX-SPECIFIC GENETIC EFFECTS IN HUMAN REPRODUCTIVE 
BEHAVIOR  
Sex-specific genetic effects have been proposed as an important source of variation for 
complex human traits.92,93 For this reason we also ran sex-specific GWAS meta-analyses for 
both AFB and NEB and examined the genetic overlap among sexes using LD score bivariate 
regression and GCTA. Sex-specific effects refer to large differences in average phenotypes or 
biological processes known to differ between the sexes (e.g., hormonal effects). Since AFB 
and NEB are not only biological but also socio-behavioral phenotypes, it is likewise 
important to make a distinction between sex- versus gender-specific effects. Sex refers to 
biological differences between males and females, which often have their underpinnings in 
human reproduction.94 Gender refers to the socially constructed differences between men and 
women that may give rise to particular behavioral outcomes (e.g., gender-specific social 
norms regarding alcohol consumption or occupational choice). There is growing evidence 
that biological (sex) and social (gender) processes are interrelated, which in turn impacts the 
phenotypes we are examining.95 Although we recognize the importance of these distinctions, 
it is beyond the scope of the current study to disentangle sex- versus gender-effects. Rather in 
this section, we emphasize similarities and differences in the sex-specific GWAS results and 
examine the sex-specific genetic overlap of these traits.  
 
There are several key sex-specific differences in AFB and NEB. Women in contemporaneous 
populations have a comparatively lower age at first birth than men, which is attributed factors 
such as the persistent age gap between partners.96 Fecundability is strongly influenced by 
sex-specific hormonal processes and gender-specific diseases. Sex can modify both 
penetrance and expressivity of a wide variety of traits.97,98  Sex-genotype interactions can 
also theoretically act to maintain genetic variation in a population.99 Sexual antagonism, 
which is the existence of opposite genotypic effects among sexes, has been often theorized as 
one of the possible explanations for genetic differences in fertility.100 In other words, 
particular genes might influence men and women differently and could thus still be 
transmitted to the next generation. Genes that contribute to the fecundability of men may 
therefore be inherited via women’s lineage and those for women via men’s lineage.101  
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5.1 Sex-specific GWAS meta-analyses for AFB and NEB 
 
In addition to the pooled GWAS results presented in the main text, we also ran sex-specific 
GWAS meta-analyses for AFB and NEB.  The sample size for sex-specific analysis is: AFB 
women, N=189,656; AFB men, N=48,408; NEB women N=225,230; NEB men N=103,909. 
Our results indicate 6 genome-wide significant (P<5x10-08) independent SNPs for AFB 
women and 1 genome-wide significant independent SNP for NEB men. We do not find any 
genome-wide significant loci for AFB men and NEB women. Among the 6 hits for AFB 
women, 5 are also significant in the AFB pooled analysis, while 1 hit on chr8 (rs2721195; 
chr8: 145677011) is specific for women. We find a single independent SNP for NEB men 
(rs13161115; chr5:107050002) that reaches genome-wide statistical significance (P-
value<5x108), which is not significant in the NEB pooled analysis.  Supplementary Figure 34 
shows the Miami plots for AFB and NEB sex-specific analyses. Supplementary Figure 35 
depicts the QQ plots of men and women’s meta-analyses for AFB and NEB. The figure 
shows a noteworthy departure from the null hypothesis of no statistical association, in 
particular for the analysis of AFB women. 
 
Table 1 (in the main text) shows the sex-specific signals respectively for AFB and NEB. The 
effects of all significant hits in AFB have the same direction for both men and women. The 
single locus found in NEB men (rs13161115) has an opposite effect on NEB for women, 
although the p-value associated with its effect size in NEB for women does not reach 
statistical significance.  
 
5.2 Genetic overlap among sexes using LD score bivariate regression 
We used LD score bivariate regression8 to estimate the genetic correlation among men and 
women based on the sex-specific summary statistics  of AFB and NEB meta-analysis results. 
For each phenotype, we used the “eur_w_ld_chr/” files of LD Scores computed by Finucane 
et al. and made available on https://github.com/bulik/ldsc/wiki/Genetic-Correlation. These 
LD Scores were computed with genotypes from the European-ancestry samples in the 1000 
Genomes Project using only HapMap3 SNPs. Only HapMap3 SNPs with MAF>0.01 were 
included in the LD Score regression. Our estimates indicate a genetic correlation of rg=0.86 
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(SE=ì0.052) among sexes for AFB and rg=0.97 (SE=0.095) for NEB. These results indicate a 
large genetic overlap among sexes for both AFB and NEB, which is statistically different 
from zero. We additionally test whether these genetic correlations support the null hypothesis 
of complete genetic overlap among sexes (rg=1). We reject this null hypothesis for AFB, 
indicating sex-specific genetic variants for AFB.  We do not find any evidence of sex-specific 
signals for NEB.  
5.3 Genetic overlap among sexes using GCTA 
We additionally estimate the degree of genetic overlap among sexes using Genomic-
Relatedness-Matrix Maximum Likelihood (GREML)46 on six cohorts for which we have 
direct access to genotypic data.46,47,102–104  For the GREML analyses, we combine data from 
six cohorts: HRS, EGCUT, QIMR Lifelines Cohort Study, TwinsUK and STR 
(Nwomen=20,966; Nmen=17,024, see Supplementary Table 33 for descriptive statistics). We 
used GCTA46 to construct a Genome-wide Relatedness Matrix (GRM) 𝑨𝒏×𝒏 and estimate the 
models. For quality control (QC), we included in the analysis only HapMap3 SNPs with an 
imputation score larger than 0.6. We additionally excluded SNPs with a missing rate larger 
than 5%, MAF lower than 1% and which failed the Hardy-Weinberg equilibrium test for a 
threshold of 10./0. We applied these QC steps for each cohort and repeated again on the 
merged dataset. After QC, 847,278 SNPs could be utilized to estimate the GRM between 
individuals.  
 
5.4 Bivariate GREML analysis 
First, we fit a bivariate GREML model as proposed by Lee et al.104 treating the fertility traits 
of men and women as different traits.102 To account for potential country heterogeneity, we 
estimated genetic variation from within cohorts only (𝜎2_45% ), setting the GRM between 
individuals from different cohorts equal to zero.50 This allows us to avoid the potential bias 
due to differences in allele frequency across different countries. The GRM can be depicted as 
a block matrix composed by six within-cohort GRMs (𝐀𝒈𝒘𝒄) containing only values for pairs 
of individuals within cohorts.  
 
The variance-covariance matrix of the bivariate model is shown as: 
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𝑽 𝒇𝒎𝒆𝒏𝒇𝒘𝒐𝒎𝒆𝒏  = 𝑨𝒘𝒄_𝒎𝒆𝒏𝜎2_45_?@A% + 𝐈𝜎@_45_?@A%𝑨𝒘𝒄_𝒎𝒆𝒏_𝒘𝒐𝒎𝒆𝒏𝜎2_45_?@A_4D?@A% 						𝑨𝒘𝒄_𝒎𝒆𝒏_𝒘𝒐𝒎𝒆𝒏𝜎2_45_?@A_4D?@A%								𝑨𝒘𝒄_𝒘𝒐𝒎𝒆𝒏𝜎2_45_4D?@A% + 𝐈𝜎@_45_4D?@A%  
 
whereas 𝒇𝒎𝒆𝒏  and 𝒇𝒘𝒐𝒎𝒆𝒏  are vectors of length 𝑁?@A	𝑎𝑛𝑑	𝑁4D?@Aof fertility phenotypes 
(NEB or AFB), with N being the respective sample size of the subsets, 𝑨𝒘𝒄_𝒎𝒆𝒏_𝒘𝒐𝒎𝒆𝒏 is the 
within population GRM for all individuals, 𝑨𝒘𝒄_𝒎𝒆𝒏 is the within cohorts GRM for men, and 𝑨𝒘𝒄_𝒘𝒐𝒎𝒆𝒏  for women. The parameter 𝜎2_45_?@A%  is an estimate of the genetic variance 
component for men and 𝜎2_45_4D?@A%  and 𝜎2_45_?@A_4D?@A%  the genetic covariance across 
sexes. 𝐈  is the identity matrix, and 𝜎@_45_4D?@A% , 𝜎@_45_?@A%  the respective, sex-specific 
residual variances within cohorts. We present the variance components standardized for the 
phenotypic variance 𝜎I%. The correlation of the genetic factors are estimated as:  𝑟KL_MN_OPQ_MROPQS = 𝜎2_45_?@A_4D?@A% / 𝜎2_45_?@A% ∗ 𝜎2_45_UV?@A%  
 
We find significant heritability for NEB and both sexes 𝜎2_4I% /𝜎$% = 0.13 (SE=0.057, P=0.01) 
for men, and 0.08 (SE=0.04, P=0.01) for women (see Supplementary Table 34 for full 
results). This means that around 10% of the variance in NEB is explained by common SNPs 
for both sexes. The estimated genetic correlation across sexes is 0.98 (SE=0.44) and a 
likelihood ratio-test against a perfect genetic correlation across sexes has a p-value of 0.5. We 
therefore cannot reject the null-hypothesis that genetic effects are the same across sexes. 
 
For AFB we find a very similar pattern of sex specific SNP-based heritabilities of around 
0.10 and a genetic correlation of 1.00 (SE=0.67, P=0.5 when testing against 1). These results 
also cannot reject the null-hypothesis that genetic effects on AFB are the same across sexes. 
 
5.5 Analysis of differences between sample and effect sizes 
Table 1 in the main text did not include the Ns of the sex-specific analyses. It is, however, 
important to place the p-value of women and men in context and clarify why the effect size 
for some loci is similar in men and women but the p-value is not. This could reflect a 
difference in sample size, or it may reflect a difference in variance. Supplementary Table 32 
shows all of the sex-specific sample sizes, p-values, z-scores and the p-value differences 
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between males and females by each SNP. It indicates sex-specific effects and a statistical test 
showing the differences between effect sizes.   
 
The statistical test is based on the differences between male and female Z-scores: 
𝑍XYZZ = 𝑍\𝑁\ + 𝑍%𝑁%1𝑁\ + 1𝑁% ~𝑁(0,1) 
Supplementary Table 32 reports the P-value differences of this Z-score test. Despite the fact that p-
values differ among the sexes, it seems plausible that the differences are mainly due to variation in 
sample size and not attributed to different effect sizes. Our results show that the only locus that has a 
statistically different effect between men and women after taking into account the number of test 
conducted is rs13161115 in chromosome 5, where the effect is significant only in men and the 
direction of the effect differs among sexes. 
 
5.6 Discussion 
Sex-genotype interactions and sexual antagonistic effects may affect the transmission of traits 
across generations and has been proposed as a possible source of genetic variation in fertility 
traits.101 Fecundability is strongly influenced by sex-specific hormones and infertility causes 
differ between men and women.105 Our results show little differences in the genetic 
architecture of the fertility traits (AFB, NEB) of our study between men and women. Out of 
12 independent loci for AFB and NEB, only two have a sex-specific effect. Moreover, all the 
signals found for AFB and two out of three signals in NEB, have a consistent direction across 
the sexes. We found a high genetic correlation among men and women for both AFB and 
NEB, both using LDscore bivariate regression and GREML bivariate analysis. This suggests 
that most of the genetic effect of fertility due to common SNPs is shared across sexes. 
However, using LDscore regression, we reject the null hypothesis of rg=1 for AFB (P=0.007). 
A possible explanation of why we have not found more evidence for sex-genotype 
interactions may attributed to the fact that we analyzed only common variants and that we 
restrict our analysis to autosomal chromosomes. Moreover, our sex-specific meta-analysis 
may be underpowered to discover sex-specific loci.  
 
When we compare Table 1 and 2, we note that in addition to the chr 5 locus for NEB, the chr 
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2 locus for AFB also shows a discrepancy between a sex-specific effect in the GWAS 
(women only) versus the (known) function of a candidate gene (AFF3). It would be 
premature to draw any firm conclusions since little is known about the role of AFF3 (chr 2) 
and EFNA5 (chr 5) in reproduction. For a substantial number of loci there are differences in 
the p-value between men and women, but the effect size suggests the association is present in 
both sexes. Only four loci seem to have a convincing null effect in men (rs1160544, 
rs10056247, rs2721195) or women (rs1316111). We would encourage functional follow-up 
studies on these points to further our understanding of human reproduction. 
 
6. POLYGENIC SCORES PREDICTION 
We performed out-of-sample prediction using cohorts for which we have direct access to 
genotypic data. We calculated polygenic scores for AFB and NEB, based on GWA meta-
analysis results and used regression models to predict the same phenotypes in four 
independent cohorts: HRS, Lifelines, STR and TwinsUK. We ran ordinary least-squares 
(OLS) regression models and report the R2 as a measure of goodness-of-fit of the model. In 
addition, we tested how well our polygenic scores for NEB could predict childlessness at the 
end of the reproductive period (using age 45 for women and 55 for men). Since age at first 
birth is observed only in parous women, we adopt an additional statistical model to account 
for censoring and selection. Finally, we also tested the predictive value of our polygenic 
scores for AFB for age at menarche (using TwinsUK) and age at menopause (using 
Lifelines). 
 
6.1 Linear polygenic scores for AFB and NEB 
We ran meta-analyses of the pooled AFB and NEB phenotypes, excluding each of the 
independent cohorts. Using these summary statistics, we constructed linear polygenic scores 
using the effect sizes from the original meta-analysis.1  We constructed all scores using the 
software PLINK and PRSice2,3 based on best call genotypes imputed to 1000G.  For each 
phenotype, we calculated nine different scores using different p-value thresholds: 5e-08, 5e-
07, 5e-06, 5e-05, 5e-04, 5e-03, 0.05, 0.5 and 1. Results are clumped using the genotypic data 
as a reference panel for LD structure.  
 31 
 
 
We first regressed each phenotype on birthyear, its square and cubic to control for nonlinear 
trends in fertility, and the first 10 principal components, following the analysis plan 
distributed to the cohorts. If the cohort included both men and women, we included sex as a 
covariate in the regression models. Next, we regressed the residuals from the previous 
regression on the polygenic score. We performed a set of Ordinary Least Squares (OLS) 
regressions where we calculated R2 as an indicator of goodness-of-fit of the regression model. 
For twin studies (STR and TwinsUK), we included only one MZ twin in the analysis and 
used clustered standard errors at the family level. To obtain 95% confidence intervals (CI) 
around the incremental R2’s, bootstrapping was performed with 1,000 repetitions.  
 
The results of the polygenic score analyses are depicted in Supplementary Figure 2. The 
sample-size-weighted mean predictive power of the AFB score constructed with all SNPs is 
0.9%, while the NEB score predictive power is 0.2%.  
 
6.2 Linear polygenic scores for infertility 
We used the score for NEB in an additional analysis to predict the probability to remain 
childless at the end of the reproductive period. Despite its limited predictive power for 
number of offspring, our analysis shows that an increase of one standard deviation of the 
polygenic score is associated with a decrease of around 9% in the probability to remain 
childless for women, with no significant differences among men (see Supplementary Table 
21). The results are consistent across different cohorts.  
 
6.3 Additional statistical models for censoring and selection 
There are two limitations when studying the genetic determinants of AFB. The first is that 
this measurement is assessed only for men and women who ever became parents and does not 
take into consideration that a proportion of respondents are still at risk of having a child (i.e., 
did not have a child yet by the date of the interview) or will remain childless. This problem is 
commonly referred in the statistical literature as ‘right censoring’, since the outcome is not 
observed for all respondents, despite the fact that part of the respondent are still ‘at risk’ of 
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experiencing childbirth.106 The second problem is statistical selection. Individuals with a 
measurement of AFB may be genetically different from individuals who remain childless. If 
childless individuals are different from the general population, the association results on AFB 
may be biased by selection problems. To investigate these two issues further, we estimated 
additional statistical models.  
 
To control for right-censored data, we estimated semi-parametric Cox regression models4 in 
which we estimate the effect of the polygenic score (PGS) on increasing the hazard of having 
a child conditional at each age. In other words, it is a model that estimates the impact of AFB 
PGS on yearly AFB, which will allow us to assess whether an increase in the AFB PGS is 
associated with a reduced risk of childbearing at each yearly age interval. This class of 
models takes into account censoring and is widely used to study fertility timing.107 Our 
results show that the calculated PGS for AFB based on all SNPs is associated with an 
increased risk of childbearing at any age. The median AFB for men in the pooled sample is 
28 and 26 for women. The hazard ratio of the PGS for AFB is 0.92 for women and 0.97 for 
men. This means that an increase of one standard deviation in the PGS is associated with an 
increase of 8% of AFB for women and 3% for men. Results for different cohorts and sex are 
depicted in Supplementary Table 22. Since this is a survival model that handles right-
censoring (i.e., that the event of AFB did not occur by the observation time), the 
interpretation is that an increase in one standard deviation of the AFB PGS is associated with 
a reduction of 8% and 3% respectively for women and men in the hazard ratio of 
reproduction.  
 
To control for selection, we estimated bivariate Heckman selection models in which we 
estimate the probability to be ‘eligible’ or at risk for AFB in a two-step procedure. Since we 
are interested in possible genetic differences among men and women who ever had children 
with respect to childless individuals, we used the PGS for NEB to model the probability to be 
at risk for AFB.  The results from the Heckman selection models indicate slightly lower 
coefficients than OLS regression models but no substantial differences (see Supplementary 
Table 35 for details). 
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6.4 Linear prediction of age at menarche and age at menopause using AFB linear score 
 
As an additional test, we examined whether the aforementioned PGS scores for AFB and 
NEB can predict related fertility traits such as age at menopause and age at menarche. We 
used the age at menopause measurement included in the Lifelines cohort. Age at menopause 
is measured with the question: “At which age have you had your last menstrual period?” We 
excluded women from the sample who reported to have had their last menstruation before 
age 30 or after age 60. The median age at natural menopause (ANM) in the sample is 45.  
Our results show that the PGS for AFB is associated with a later ANM. Since a substantive 
proportion of the sample of women in Lifelines is still in the pre-menopausal period, we 
estimated a proportional hazard model (Cox regression) in which we estimate ANM as a 
function of PGS for AFB. Our estimates indicate that having higher predisposition for AFB is 
associated with a later ANM. The hazard ratio estimate 0.97 indicates that an increase of one 
standard deviation of the PGS for AFB is associated with a decrease of ANM of about 3%.  
We used TwinsUK to model age at menarche. Our estimates indicate that an increase of one 
standard deviation on the PGS of AFB is associated with an increase of 0.06 years on age at 
menarche.5 Results are depicted in Supplementary Table 23. 
 
6.5 Association of menopause variants with AFB 
We also examined whether menopause variants are associated with AFB. We calculated a 
PGS of age at menopause based on the recent GWAS results from Day et al. (2015)108 and 
applied them to LifeLines and TwinsUK. The results for this analysis can be found in 
Supplementary Table 36 and shows no predictive power of the menopause genotype on AFB. 
This is consistent with the lookup exercise presented in S7.2, where none of our loci were 
significantly associated with age at Menopause. There might be several reasons why the LD 
score regression indicates a positive genetic correlation but we do not find evidence for 
specific loci. First, one or both of the studies may be underpowered and thus unable to 
identify a sufficiently large number of variants. Second, the correlation between the two traits 
may be spurious and mediated by other traits (e.g., age at menarche). We agree that it would 
be very interesting to pursue this in further research.   
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6.6 Discussion: The predictive power of polygenic scores 
We acknowledge that the predictive power of the polygenic scores created from a meta-
analysis of over 60 GWASs is only a fraction of what has been found in previous twin and 
family1 and even GREML studies.38 Several reasons have been noted for this ‘missing 
heritability’ problem,109 including non-additive genetic effects,49 epistatic effects,110 rare 
variants and inflated estimates from twin studies due to differential sharing of environmental 
factors in monozygotic and dizygotic twin pairs.111 Other factors that can explain the lower 
magnitude of effects are also plausible. Firstly, as we elaborate in Section S1.5, human 
reproductive behavior is not only biological, but also strongly related to environmental 
factors, and we should therefore not expect to find large independent genetic effects. We do 
not expect the PGS score to explain part of the variance attributable to environmental factors 
(i.e., the C and E in twin studies), but rather argue that these environmental factors are likely 
much stronger than genetic factors for these behavioral outcomes. As argued recently 
elsewhere,39 it is vital to note that deep genetic analyses need to be united with strong and 
direct phenotypic measures. Although AFB and NEB are robustly measured, they inherently 
include a mix of voluntary (choice) and involuntary (infertility) measures. To overcome this 
problem, future innovations must unite rich genetic data with equally rich and precise 
phenotypic data collected precisely and continuously over several generations.  
 
A second factor is that when studying phenotypes with behavioral component, GWAS 
discoveries are potentially limited by heterogeneity across birth cohorts and populations (e.g., 
countries) and particularly prone to gene-environment interaction. Fertility behavior has been 
demonstrated to be strongly environmentally determined and modified (e.g., by the 
introduction of effective contraception).18 Although we examine gene-environment 
interaction across birth cohorts in Sweden in the Supplementary Note (section 10.1), in future 
research we will explore whether gene-environment interaction plays a role across birth 
cohorts and countries, with preliminary evidence suggesting that this is the case.112 This is in 
line with recent research that has shown cohort differences in the genetic influence on 
smoking over time.113 
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7 GENETIC CORRELATIONS 
 
7.1 Estimating genetic overlap using LD score regression 
The estimates of the LD score regression reported in the main text was based on the LD-score 
regression method, which was developed by Bulik-Sullivan et al. (2015).90 Here we describe 
in more detail how these estimates were computed and the genetic correlation we estimated 
between AFB and NEB and 27 publicly-available GWAS results (Supplementary Table 25 
and graphed in Figure 3 in the main text). We focus on infertility traits, developmental traits, 
anthropometric traits, neuropsychiatric conditions and selected behavioral traits. LD score 
regression works even in the presence of sample overlap and only requires summary statistics 
and a reference panel from which to estimate SNP’s “LD score”, which measures the amount 
of genetic variation tagged by a SNP.  
 
The approach requires GWAS summary statistics for all SNPs in our GWAS and a reference 
sample from which the LD can be estimated in order to estimate the LD score regression.86 
The method is written formally based on the following relationship:  
 𝐸 𝑧\c𝑧%c = 𝑁\𝑁%M ℓc𝜌2 + 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡, 
 
Where 𝑧lc is the z-score of SNP j from the GWAS of trait k (k=1,….,20), 𝑁l is the sample 
size of the GWAS of trait k, ℓcis the LD Score of SNP j, M the number of SNPs included in 
the GWAS, 𝜌2 the genetic covariance between traits 1 and 2, with the regression intercept 
represented by intercept. The slope from the regression of 𝑧\c𝑧%c  on 𝑁1𝑁2ℓ𝑗 can be used to 
estimate the genetic covariance between the two traits. We are also able to estimate the 
heritabilities of the two traits, ℎ2\%  and ℎ2%%  from the univariate LD score regressions of traits 1 and 
2. It therefore follows that an estimate of the genetic correlation is:  𝑟2 = 𝜌2ℎ2\% ℎ2%%  
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We use the file of LD scores computed by Finucane et al.91 using genotypic data from a 
European-ancestry population (eur_w_ld_chr). LD Scores are computed with genotypes from 
the European-ancestry samples in the 1000 Genomes Project using only HapMap3 SNPs. We 
additionally follow the common convention of restricting our analyses to SNPs with MAF > 
0.01, thus ensuring that all analyses are performed using a set of SNPs that are imputed with 
reasonable accuracy across all cohorts that contributed towards meta-analyses. 
 
The standard errors (SEs) produced by the LDSC python software package uses a block 
jackknife over the SNPs. This influences the interpretation. Conventional standard errors are 
interpreted as measuring the variability of the estimate holding the covariates constant, but 
drawing on a new set of individuals. In this technique, SEs are interpreted as the variability of 
the estimate holding the sample constant, but drawing a new set of SNPs.  
 
7.2 Estimating the genetic correlation between AFB and NEB 
The negative relationship of late AFB with lower NEB7,10,114 is well-established and 
consistent in advanced societies. Behavioral genetic models, based on twin or family studies 
show that this correlation is partially genetic, suggesting that natural selection favored a 
younger age at first birth over the Twentieth century.1,38,115  
 
A recent study on genetic basis of fertility traits using molecular genetic data shows that 
common genetic variants influence NEB and AFB in a large sample of unrelated women.38 
Their results indicate a significant negative genetic correlation (rg=–0.62, SE=0.27) between 
AFB and NEB. This finding implies that individuals with genetic predispositions for an 
earlier AFB had a reproductive advantage. We replicated the analysis of Tropf et al.38 on a 
large sample of women from the Women General Health Study (WGHS, sample size 
N=40,120). We found a negative genetic correlation (rg=–0.26, SE=0.13) between AFB and 
NEB. The results were limited to women and applied to a limited sample. We extend this 
work using LD score bivariate regression86,90 on AFB and NEB on both men and women to 
identify the extent of cross-trait genetic correlation. 
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The LD score bivariate estimates indicate high negative correlation rg=–0.66 (SE=0.03, p-
value=1.03x10-102) between AFB and NEB. This result is consistent both in men and women 
and is in line with the phenotypic correlation. Genetic correlation of fertility traits among 
women is slightly higher (rg=–0.66, SE=0.04) than men (rg=–0.58, SE=0.07). Overall these 
results show a considerable genetic overlap between NEB and AFB (as found in section 3). 
However, since the genetic overlap is statistically different from 1 for both men and women, 
these results indicate the existence of trait-specific genetic components.  
 
7.3 Results: phenotypic correlations with human reproductive behavior 
As discussed in the main text, we used information from 27 publicly available GWAS results 
to examine phenotypic correlations between AFB and NEB (Supplementary Table 25 and 
Figure 3 in the main text).  These included: nine developmental  traits, some of which are 
directly related to the reproductive span (age at menarche,116 age at menopause,117 Tanner 
stage,118 age at voice breaking for males,119 polycystic ovary syndrome (PCOS),120 age at first 
sexual intercourse,23 DZ Twinning,121 birth length,122 birth weight123), four behavioral traits 
(years of education,76,79 cigarettes per day,124 ever smoked,124 age onset smoking124), seven 
personality and neuropsychiatric traits (neuroticism,125 openness, schizophrenia,126 bipolar 
disorder,127 subjective well-being,80 Alzheimer’s disease,128 autism129), four cardiometabolic 
traits (LDL cholesterol,130 triglycerides,130 type 2 diabetes,131 fasting insulin levels132), and 
three anthropometric traits (BMI,133 height,87 waist-hip ratio134). 
 
As shown in Fig. 3 and Supplementary Table 25  (P-values in bold indicate Bonferroni 
correction (P-value<0.05/27=1.85x10-03)), AFB is positively correlated with years of 
education, age at menarche, age at menopause, age at voice breaking, age at first sexual 
intercourse and adult height, while it is negatively correlated with PCOS, adult BMI and 
waist-hip ratio, triglycerides, diabetes and fasting insulin level. Once multiple testing is 
controlled for, years of education and age at first sexual intercourse are the only traits 
significantly correlated with NEB (P-value<2.25x10-03), and the direction is negative for both 
traits.  
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7.4 Discussion 
7.4.1 Human development 
AFB was shown to be positively correlated with the development measures of age at 
menarche, age at menopause, age at voice breaking and age at first sexual intercourse. A later 
age of menarche (AOM) has been associated with subfecundity and infertility in adulthood. 
A recent large cohort study of 73,107 women135 demonstrated that women who reached 
menarche later than 15 years (compared to a reference group of girls with an AOM at 13 
years) had a higher risk of infertility. Women younger than 11 years at AOM had lower odds 
of subfecundity and all results remained significant also after adjusting for women’s age of 
pregnancy. Some studies, however, have also found a significant relationship between early 
AOM with diminished functional ovarian reserve later in life among infertile women.136 
There is also evidence of a small increased risk of endometriosis associated with early 
AOM.137 
 
Stolk et al. (2012)138 linked age at menopause to genes implicated in DNA repair and 
immune function. A recent study reported genetic correlations indicating shared aetiologies 
in both sexes between the timing of puberty and BMI, lipid levels, type 2 diabetes and 
cardiovascular disease.139 Fertility timing has been positively associated with age at 
menarche and age at first intercourse. Although previous research has largely focused on 
identifying genes related to menopause and menarche that mark the end the beginning and 
end of the reproductive career, it is also possible that observed fertility (AFB, NEB) 
influences the subsequent age at menopause and ovarian aging. Exploring these overlaps and 
associations would be an interesting area for future research.  
 
Results from a genetic study of age at first sexual intercourse (AFS) linked AFS to variation 
in pubertal timing, but also personality characteristics related to high risk-taking and low 
neuroticism.23 We examine the link with AFS and neuropsychiatric disorders in a later 
section (Section 7.4.5).   
 
7.4.2 Cardiometabolic traits 
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Having more AFB-increasing alleles was also significantly associated with a lower genetic 
scores for triglycerides, Type 2 Diabetes and fasting insulin level. Pregnancy for women 
results in considerable alterations in the cardiovascular system.36 Reproductive events are 
associated with alterations in blood lipids and blood pressure and may therefore influence 
determinants of coronary heart disease. As with diabetes, there are mixed findings regarding 
the link between age at birth, parity and coronary heart disease (CHD). Some studies have 
linked the number of children and CHD risk with the prevalence lowest among those with 2 
children with a linear increase with each additional child.22 These researchers have argued 
that it is not the pregnancy per se that has a biological impact but rather that the lifestyle risk 
factors associated with childrearing leads to obesity which in turn results in increased CHD in 
both sexes. Yet, they maintain the argument that biological responses of pregnancy may have 
additional adverse effects in women.  
 
Other studies attempted to elucidate the mechanisms linking multiparity to cardiovascular 
disease demonstrating that repeated pregnancies induce long-term changes in cardiovascular 
regulation in women due to the changes in vascular compliance and endothelium-dependent 
vasoconstriction, which in turn increase the risk for CHD in multiparous women.36 A recent 
study related early puberty timing to higher risks for both Type 2 Diabetes and cardiovascular 
disease.27 It may be however, that just as with the studies on GDM (gestational diabetes 
mellitus) described shortly, retrospective and cross-sectional approaches may have 
limitations related to selectivity and unobserved confounding factors. A prospective study in 
the US found that a younger age at menarche was only weakly associated with CHD and that 
nulliparous women only had a slightly higher rate of CHD compared to parous women. They 
also found no change in the risk with an increasing number of births or any association with 
the age at first birth concluding that there is no clear link between reproductive history and 
risk of CHD.140 Further research is required to establish whether there is a true causal link 
and underlying genetic and biological mechanisms to explain the association between 
reproductive history and cardiometabolic traits.  
 
There does, however, appear to be a link with the cardiometabolic traits that we measure in 
this study with infertility. Total cholesterol, triglycerides, LDL cholesterol levels and fasting 
insulin levels have been shown to be statistically higher in groups with endometriosis 
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compared to controls.141 Endometriosis is estimated to occur in 5-10% of premenopausal 
women with ~50% experiencing problems conceiving.34 A recent study also revealed a link 
between endometriosis and obesity-related traits.142 Other studies have also linked the impact 
of maternal cholesterol metabolism to ovarian follicle development and fertility.143 The role 
of the low-density lipoprotein receptor in cellular metabolism in inhibiting human 
reproduction has likewise been established.144 Others have linked metabolic syndrome, which 
is a compilation of symptoms such as a high BMI (obesity), type 2 diabetes, dyslipidemia, 
and hypertension with an increased prevalence of infertility in men.145  
 
A wide body of research links reproductive history to Type 2 Diabetes. Early studies found 
that nulliparity and multiparity or grand parity (5 or more children) was associated with 
higher levels of fasting glucose and insulin levels among nondiabetic women.146–148 
Multiparity has been associated with higher risks of cardiovascular disease in both women 
and men27,149,150 and higher insulin resistance and type 2 diabetes.149,151 Other research found 
that high parity was associated with insulin resistance and type 2 diabetes, which even after 
adjusting for confounders (socioeconomic, higher obesity, inflammatory markers) grand 
parity is associated with a 27% increased risk for diabetes (95% CI, 1.02-1.57).151 
 
It is essential to note, however, that early cross-sectional and retrospective studies did not 
control for age, body size or socioeconomic status. Later cross-sectional studies that 
controlled for the abovementioned factors, continue to produce highly mixed results (for a 
review see ref 152). A key limitation is that many of the previous studies lack universal GDM 
(gestational diabetes mellitus) screening and did therefore not measure preconception 
glycaemia or glucose intolerance during pregnancy. A systematic review and meta-analysis 
demonstrated that women who had gestational diabetes had a seven-fold greater risk of 
developing Type 2 Diabetes.152 This suggests that once GDM status is accounted for, the 
direct parity effect will be very small or null. One the other hand, unobserved conditions such 
as PCOS, obesity or insulin resistance could in fact cause infertility (nulliparity) which would 
in turn lead to an underestimation of the association.  
 
Gunderson et al. (2007)153 examined whether childbearing increased the incidence of Type 2 
Diabetes after preconception glycaemia and gestational glucose intolerance were controlled 
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for. They concluded that childbearing did not elevate the incidence of diabetes among those 
without GDM (i.e., normal glucose tolerance during pregnancy). It was GDM rather that was 
associated with the highest risk of developing diabetes, which remained even after controlling 
for family history of diabetes, preconception glycaemia and obesity. Another study using 
GDM screening found that a woman’s age remained a strong predictor even after adjusting 
for prior GDM history, mirroring the general historical increase in GDM (and related levels 
of obesity) across time in certain groups. A logistic regression analysis also showed that 
mother’s age at birth (OR 95% CI per 5 years 1.6–1.8) was significantly associated with 
GDM. Parity was not significantly associated with GDM and had no effect on the GDM 
increase over time.154  
 
7.4.3 Anthropometric traits 
A considerable body of literature links anthropometric traits (such adult height, BMI and 
increasingly waist-hip ratio) with fertility timing and success.133,155 Anthropological research 
argue that shorter women may have more reproductive success because of the trade-off 
between investing in energy in growth or reproduction.156 Moreover, taller women appear to 
become fertile at a later age (e.g., age at menarche) than shorter women, and women who 
have children at an early age reach a shorter adult height, which may result in a negative 
relationship between women’s height and reproductive success.155,157 The relationship 
between men’s height and fertility is more complex. One paper revealed a curvilinear 
association between men’s height and number of children in a nationally representative 
sample of US respondents.158 Men of average height appear to have a higher reproductive 
success than either short or tall men. The relationship between height and number of children 
in advanced societies is not always negative. A recent paper showed that in the Netherlands – 
the country with the highest average population height – the relationship is the opposite.155 A 
possible mechanism through which height may affect fertility is sexual selection and 
assortative mating. There is a certain degree of homogamy in anthropometric traits among 
spouses, even after controlling for a variety of socio-economic traits.159,160  
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BMI and waist-hip ratio (WHR) is another area of research often linked with fertility success, 
particularly in couples seeking ART treatment.161 Both a very low and a very high BMI have 
been found to delay both the timing and number of children in both men and women.162  
Waist-hip ratio measures body fat distribution and serves as a more accurate predictor of 
metabolic consequences independent of overall adiposity. A study locating new loci for 
WHR also found that seven of the loci exhibited marked sexual dimorphism, or in other 
words, that the genetic loci that modulate fat distribution have a stronger effect on WHR for 
women than men, suggesting strong gene-by-sex interactions.163  
 
7.4.4 AFB and educational attainment 
As described already in detail in Supplementary Note Section 1.5, the strong relationship 
between AFB and years of education is not surprising, since educational attainment is 
associated with higher AFB and a lower NEB in most advanced societies.54,164 As discussed 
previously, the study of the relationship between higher educational attainment and 
reproduction has been a central focus within demography and related social 
sciences.7,10,58,114,165 The majority of the research demonstrates that achieving higher 
education (particularly of women) operates to postpone AFB. Other studies have shown that 
fertility postponement may be related to higher cognitive ability,166 but additional research is 
required to separate cognitive scores from social environment (e.g., family environment, 
social class). Others have found that after controlling for age, physical maturity and mother’s 
education, there is a significant curvilinear relationship with intelligence and early sexual 
intercourse with both very low and very high intelligence operating as a protective factor 
against early sexual activity.167  Further careful research in this area would be necessary to 
understand the relationship.  
 
7.4.5 AFB, personality and neuropsychiatric disorders 
The results of the LD score regression did not find any significant association with 
neuroticism, openness, schizophrenia, bipolar disorder, well-being, Alzheimer’s disease or 
autism, so we will only touch upon this topic briefly. Personality has been demonstrated to be 
predictive of fertility intentions20,168 and the timing of childbearing.169,170 The finding that 
AFB is negatively correlated with neuroticism has also been found in previous non-genetic 
 43 
 
studies linking AFB to personality traits.171,172 A bidirectional effect between fertility and 
psychological development has likewise been documented.168,173 This may suggest that the 
interaction between genetic and environment factors could be interpreted as genetic 
influences on fertility that have an effects on both fertility behavior and psychological 
outcomes. Since personality, educational attainment and cognitive ability are largely formed 
before individuals enter into their childbearing years, it is plausible that personality and 
cognitive traits are likely causal and precede fertility variables.174 A recent study also 
demonstrated a genetic overlap between schizophrenia and AFB, showing a U-shaped 
relationship. The study confirmed that the schizophrenia risk profile score significantly 
predicted the relationship between maternal age and risk of schizophrenia in offspring.16  
 
7.4.6 Smoking behavior 
The strong negative correlation of a lower genetic risk of smoking (less cigarettes per day, 
lower chance to have ever smoked and later age of onset smoking) with a later AFB could 
operate via two mechanisms. First, it is well established that cigarette smoking has a 
detrimental biological effect on ovarian function and spermatozoa. There is an established 
link of a longer time to conception and decreased fertility with the increasing number of 
cigarettes smoked per day.175 Other studies have linked cigarette smoking to infertility such 
as problems with preimplantation176, shrinking the size and quality of oocytes177, and 
abnormal spermatozoa by decreasing sperm motility in smokers.178 A second potential 
mechanism is that the earlier onset of smoking and higher number of cigarettes smoked per 
day is also highly stratified by socioeconomic status. Smoking and low socioeconomic status 
are often linked to other environmental risk factors and a higher co-morbidity for other 
diseases.179 Smoking is thus often a marker for structural, health and material disadvantage in 
addition to being concentrated in groups with the lowest levels of education.180 
 
7.4.7 Limitations of LD score regression genetic correlations 
Although LD score regression is a powerful tool to identify possible relationships between 
traits, we acknowledge that it does not allow us to establish causal directions or relationships 
or to adjust for potential mediating factors. The relationship between many of the traits 
discussed in this section is highly complex with potential bi-directional mechanisms. Further 
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studies are required to explore these relationships and establish whether the genetic risk 
related to AFB and NEB are either partially or fully mediated by other factors.  
 
URLs. 
 
The LDSC software is available at the website: http://www.github.com/bulik/ldsc;  
GWAS summary statistics are available at the following websites: PGC (psychiatric) 
summary statistics, http://www.med.unc.edu/pgc/downloads; GIANT (anthropometric) 
summary statistics, http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files; 
data on birth length, birth weight, Tanner stages have been contributed by EGG Consortium 
and has been downloaded from www.egg-consortium.org.; data on glycaemic traits have 
been contributed by MAGIC investigators and have been downloaded from 
www.magicinvestigators.org; DIAGRAM (type 2 diabetes) summary statistics, 
http://www.diagram-consortium.org/; SSGAC (educational attainment) summary statistics, 
http://www.thessgac.org/.
 45 
 
8. LOOK-UP OF LEAD SNPS IN AFB GWAS FOR AGE AT MENOPAUSE AND 
AGE AT MENARCHE 
 
Following the results on genetic overlap with other phenotypes we tested – in a quasi-
phenotype replication setting – whether the SNPs strongly associated with AFB in women are 
empirically plausible candidates SNPs for age at menarche and age at menopause. Our results 
reported in the previous section (Supplementary Note, Section 7) indicate a strong genetic 
correlation between these traits, suggesting a common genetic basis of reproductive behavior 
and reproductive life span.  
 
Here we use a two-stage approach that has been applied in other contexts.80,181 Since we are 
only looking at phenotypes measured among women with menarche and menopause, we 
started our analysis from the meta-analysis results from the AFB sample of women. In the 
first stage, we conduct a meta-analysis of age AFB excluding the cohorts that were part of the 
meta-analysis of the phenotype we intend to replicate. This step reduces the risk of overlap 
between the AFB sample from which the candidate SNPs are drawn and the sample used for 
testing the other phenotypes. We merged these SNPs with the publically available association 
results on the most recent GWAS on age at menarche116 and age at menopause117 from the 
Reprogen consortium websiteb. We first merged the two association files and dropped SNPs 
that are not present in both the files. We aligned the alleles and the effects direction using the 
software package EasyStrata.182 We then selected the independent SNPs with a p-
value<1x10-5, using the clump procedure in PLINK83, using the same settings described in 
section SI.2 (1000Kb window and LD threshold of R2>0.1) to identify the most significant 
SNPs in associated regions included in both files. We define “prioritized SNP associations” 
as those that passed the Bonferroni correction for the number of SNPs tested 
(P=0.05/122=4.10x10-4, both in age at menarche and age at menopause).  
 
Supplementary Figure 36 shows the QQplots of the leading SNPs for AFB on age at 
Menarche (panel a) and age at menopause (panel b). Our results identified three SNPs after 
                                                
b Data downloaded in November 2015 from http://www.reprogen.org/data_download.html 
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Bonferroni-correction that can be used as good candidates for age at menarche. We do not 
isolate any clear “candidate SNP” for age at menopause. The three SNPs that we identified 
(rs9589; rs6803222; rs9858889) are all in Chromosome 3. Two of them (rs9589; rs6803222) 
lie in proximity (<500Kb) of rs2777888, which has been identified as the strongest signal in 
our AFB GWAS.  
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9. BIOLOGICAL ANNOTATION 
9.1. Identifying potentially causal variants 
We followed the post-GWAS pipeline reported by Vaez et al183 to shed light on the genomic 
context of the 12 independent genome-wide significant SNPs (Table 1 of the main text).  
In silico sequencing: For in silico sequencing, we used the data of the 1000 Genomes Project 
phase3 release of variant calls. This data set is based on the 20130502 sequence freeze and 
alignments. We used version v5a (Feb. 20th, 2015), and included only the 503 subjects of 
European ancestry (accessed April 5, 2016)184. The Variant Call Format (VCF)185 files for 
regions of 1 Mb at either side of each lead SNP were downloaded using the Tabix software 
package.186 Then, the r2 between the lead SNPs and all other bi-allelic SNPs within the 
corresponding 2 Mb area was calculated as a metric of linkage disequilibrium (LD) using the 
Plink software package (v1.07).83 All SNPs in LD with any of the lead SNPs were then 
annotated by ANNOVAR software187 (version 1 Feb 2016, accessed April 9, 2016). We also 
used Sorting Intolerant From Tolerant (SIFT)188 and Polymorphism Phenotyping 
(PolyPhen)189 prediction scores to characterize the damaging impact of the nonsynonymous 
SNPs on the corresponding proteins. These scores were obtained from Ensembl release 83 
(accessed April 11, 2016).190 
 
In silico pleiotropy analysis 
 To identify any other trait or outcome associated with these 12 independent loci, we used the 
publicly available data of the National Human Genome Research Institute (NHGRI) GWAS 
Catalog (Catalog of Published Genome-Wide Association Studies).191 We checked for 
pleiotropic effects of all lead SNPs as well as their linked variants (revealed in the previous 
phase of in silico sequencing) on other complex traits or diseases identified in previous 
GWAS studies and listed in the GWAS Catalog using ANNOVAR software187 (version 1 Feb 
2016, accessed April 9, 2016).  
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9.2. Gene-based GWAS analysis 
We performed gene-based testing with the full GWAS set (~2.5M HapMap-imputed SNPs) 
of both phenotypes using VEGAS.192,193 This software has the advantage of accounting for 
LD structure and the possibility to define a range beyond the gene bounds to include 
intergenic regions in the analysis. We defined a 50kb extra window surrounding the genes 
and considered every SNP for the gene-based analysis, ran the analyses per chromosome with 
up to 106 permutations and considered P<2.5x10-06 as the threshold for significance 
(0.05/~20.000 genes).  
9.3. eQTL and mQTL analyses 
eQTL194 and mQTL195 analyses performed by the BIOS consortium have been described 
previously. The methods described in these papers are summarized below. 
Genotype data 
The BIOS consortium used samples from five Dutch cohorts; genotype QC and generation 
was described previously for each cohort: The Leiden Longevity Study,196 The Rotterdam 
Study,197 The LifeLines-DEEP cohort,198 The Cohort on Diabetes and Atherosclerosis 
Maastricht (CODAM)199 and The Netherlands Twin Register.200 Genotype data were 
harmonized towards the Genome of the Netherlands (Genome of the Netherlands 
Consortium, 2014) (GoNL) using Genotype Hamonizer and subsequently imputed per cohort 
using Impute2 using the GoNL reference panel (v5). We removed SNPs with an imputation 
info-score below 0.5, a HWE P-value smaller than 10-4, a call rate below 95% or a minor 
allele frequency smaller than 0.05.   
9.3.2 RNA data preparation, sequencing and quantification 
Total RNA from whole blood was deprived of globin using Ambions GLOBINclear kit and 
subsequently processed for sequencing using Illumina’s Truseq version 2 library preparation 
kit. Paired-end sequencing of 2x50bp was performed using Illumina’s Hiseq2000, pooling 
samples at 10 per lane, and aiming for >15M read pairs per sample. Finally, read sets per 
sample were generated using CASAVA, retaining only reads passing Illumina’s Chastity 
Filter for further processing. The quality of the raw reads was checked using FastQC. The 
adaptors identified by FastQC (v0.10.1) were clipped using cutadapt (v1.1) applying default 
settings (min overlap 3, min length). Sickle (v1.200) was used to trim low quality ends of the 
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reads (min length 25, min quality 20). Read alignment was performed using STAR 2.3.0e. To 
avoid reference mapping bias all GoNL SNPs with MAF > 0.01 in the reference genome 
were masked. Read pairs with at most 8 mismatches, mapping to at most 5 positions were 
used. Mapping statistics from the BAM files were acquired through Samtools flagstat 
(v0.1.19-44428cd). The 5’ and 3’ coverage bias, duplication rate and insert sizes were 
assessed using Picard tools (v1.86). We estimated expression on the gene, exon, exon ratio 
and polyA ratio levels using Ensembl v.71 annotation (which corresponds to Gencode v.16). 
Overlapping exons (on either of the two strands) were merged into meta-exons and 
expression was quantified for the whole meta-exon. To this end, custom scripts were 
developed which uses coverage per base  from coverageBed and intersectBed from the 
Bedtools suite (v2.17.0) and R (v2.15.1). This resulted in base counts per exon or meta-exon. 
Expression data was first normalized using Trimmed Mean of M-values (TMM). Then 
expression values were log2 transformed, probe and sample means were centered to zero. To 
correct for batch effects, principal component analysis (PCA) was run on the sample 
correlation matrix and the first 25 PCs were removed. We saw that removing these PCs 
resulted in highest number of eQTLs detected. To ascertain that none of these 25 PCs are 
under genetic control, we ran separate QTL mapping on each principal component and 
ensured that there were no SNPs associated with them. After QC194 data was available from 
2,116 samples. 
9.3.3 Methylation data generation, mapping and normalization. 
For the generation of genome-wide DNA methylation data, 500 ng of genomic DNA was 
bisulfite modified using the EZ DNA Methylation kit (Zymo Research, Irvine, California, 
USA) and hybridized on Illumina 450k arrays according to the manufacturer’s protocols. The 
original IDAT ﬁles were extracted from the HiScanSQ scanner. We remapped the 450K 
probes to the human genome reference (HG19) to correct for inaccurate mappings of probes 
and identify probes that mapped to multiple locations on the genome. Next, we removed 
probes with a known SNP (GoNL, MAF > 0.01) at the single base extension (SBE) site or 
CpG site. Lastly, we removed all probes on the sex chromosomes, leaving 405.709 high 
quality methylation probes for the analyses. Methylation data was directly processed from 
IDAT files resulting from the Illumina 450k array analysis. After QC,195, data was available 
from 3,841 samples. 
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9.3.4 eQTL and mQTL analysis 
For each of the 12 SNPs identified in the GWAS, local (cis, exons/methylation sites < 1 MB 
from the SNP) and genome-wide (trans, exons/methylation sites > 5 MB from the SNP) 
effects were identified by computing Spearman rank correlations between SNPs and local or 
global exons/methylation sites. Bonferroni multiple testing correction was performed for the 
12 SNPs tested (P<2.5x10-06 for cis mQTL analysis, P<1x10-08 for trans mQTL analysis, 
P<1.2 x10-06 for cis eQTL analysis, P<1.3x10-08 for trans eQTL analysis). For each of the 
significant associations, the exons/methylation sites were selected, the strongest eQTLs were 
identified for these exons/methylation sites, and LD between these strongest eQTLs and the 
corresponding SNP identified in the GWAS were computed. LD was computed using BIOS 
genotypes (the genotypes used for eQTL and mQTL mapping).  
9.4. Functional variant analysis using RegulomeDB 
We used RegulomeDB201 to identify variants amongst the 322 SNPs that reached P<5x10-08 
for association with AFB and/or NEB in the meta-analysis of GWAS that likely influence 
regulation of gene expression. RegulomeDB integrates results from RoadMap 
Epigenomics202 and the ENCODE project.203 SNPs that showed most evidence of being 
functional – defined as a RegulomeDB score <4 – were subsequently examined in more 
detail in terms of effects on gene expression (eQTLs) and their protein-binding capacity 
(Supplementary Supplementary Table 6). 
 
9.4.1 Gene prioritization using four bioinformatics approaches  
Potentially causal genes for the associations identified by GWAS were identified using four 
previously described bioinformatics tools: ToppGene,204 Endeavour,205 MetaRanker,206 and 
DEPICT.207 To this end, we first retrieved positional coordinates for all lead SNPs according 
to GRCh37/hg19 using Ensembl’s BioMart. These coordinates were used to subsequently 
extract all genes located within ±40kb of lead SNPs using the UCSC Supplementary 
Notebrowser. The identified genes then served as input for ToppGene and Endeavour. Genes 
with established roles in fertility served as training genes in this procedure, i.e. BRCA1, 
EGFR, ERBB2-4, HSD17B1, RBM5, ESR1, ESR2 and FSHB. All 10 genes were used in the 
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pooled and sex-specific analyses, while ESR1, ESR2 and FSHB were not used in the analyses 
in data from men only, for biological reasons. For MetaRanker we provided SNPs that 
reached P<5x10-04 and their chromosomal position as input, together with the previously 
mentioned set of training genes. Since ToppGene, Endeavour and MetaRanker are biased 
towards larger and well-described genes, we additionally performed a gene prioritization 
procedure using DEPICT.207 All SNPs that reached P<5x10-04 in the meta-analysis served as 
input, and information on prioritized genes, gene set enrichment, and tissue/cell type 
enrichment were extracted. Genes were subsequently prioritized that reached: 1) P<0.05 in 
DEPICT; or 2) P<0.05 in ToppGene, Endeavour and MetaRanker (Supplementary Tables 11, 
12). 
 
9.5. Functional network and enrichment analyses 
DEPICT was additionally used to identify gene set, cell type and tissue enrichment analyses, 
using the GWAS-identified SNPs with P<5x10-04 as input. c  Due to the relatively small 
number of identified loci, DEPICT was only able to perform these analyses for AFB and 
NEB pooled, and AFB women. 
 
To construct a functional association network, we combined five prioritized candidate gene 
sets into a single query gene set: closest genes to the lead SNPs, closest genes to the 
nonsynonymous SNPs in high LD (r2>0.50) with the corresponding lead SNP, closest genes 
to other types of SNPs in very high LD (r2>0.80) with the corresponding lead SNP, and 
expression probe gene names of cis, and trans eQTLs. The single query gene set was then 
used as input for the functional network analysis.183 We applied the GeneMANIA algorithm 
together with its large set of accompanying functional association data.208 We used the 
Cytoscape software platform,209 extended by the GeneMANIA plugin (Data Version: 
                                                
c We initially used a threshold of P<1E-5 for association with the respective outcomes in the meta-
analyses of GWAS for SNPs to serve as input for the gene and tissue set enrichment analyses, as per 
the developers’ recommendations.206 We contacted the 1st author when this did not yield gene and 
tissue sets that were significantly enriched, and were advised to apply the slightly more lenient 
inclusion criterion of P<5E-4.  
 52 
 
8/12/2014, accessed April 24, 2016).210 All the genes in the composite network, either from 
the query or the resulting gene sets, were then used for functional enrichment analysis against 
Gene Ontology terms (GO terms)211 to identify the most relevant GO terms using the same 
plugin.210  
 
10. GENE-ENVIRONMENT INTERACTIONS 
Previous research based on twin studies shows differential heritability of fertility behavior 
across birth cohorts.212,213 With the exception of one recent mega-analysis112 and a recent 
related study,214 we are not aware of any study that examines variation at the molecular level 
to understand whether the genetic effect of AFB and NEB changes across birth cohort, level 
of education or other environmental factors. There is an implicit assumption that the genes 
associated with phenotypes are often constant across different historical, geographic or socio-
economic groups.39 In this section, we therefore examine gene-environment interaction by 
birth cohort and educational attainment.  
 
As elaborated upon already in detail in Section 1.5, there has been considerable 
environmental variation over time and among cohorts in different historical periods that has 
undoubtedly influenced AFB and NEB. It is plausible, therefore, that there are differences 
across birth cohorts (time) since individuals born in different periods face diverse 
environmental conditions, such as the introduction and availability of effective contraception, 
sexual norms and diversity in factors that ‘compete’ with fertility, such as the expansion of 
educational attainment and labor force participation of women.7  
 
This builds upon research that has examined changes across cohorts on the genetics of 
smoking. An early study adopted a twin design to demonstrate that genetic factors underlying 
smoking desistance were more important after the introduction of a restrictive legislation on 
smoking.215 A related study also showed strong genetic influences on smoking of cohorts 
born in the 1920s, 1930s and 1950s, but not for those born in the 1940s and 1960s. They link 
these differences to changes in legislation prohibiting smoking in public places.216 Using 
GREML methods and a modified DeFries-Fulker approach, a recent study likewise 
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demonstrated that there were cohort differences in the genetic influence on smoking, which 
increased over time.113  
 
It may also be the case that the PGS for AFB and NEB is moderated by educational 
attainment. If the genetic association operates differently by the level of educational 
attainment, it would provide additional insight into understanding how fertility preferences 
and education are transmitted across generations. A recent study using the HRS in the US 
suggested that natural selection has taken place in contemporary societies and that there has 
been slow selection of lower educational attainment for both sexes.214 In other words, the 
study argues that individuals endowed with genes predisposing them to more years of 
education are having fewer children and that natural selection (of those born from the 1930s 
to 1953) favors variants associated with less education. A commentary on this article39 
emphasizes four main reasons to be tentative about the conclusions that can be drawn. First, 
selection on education is weak and evolutionary changes are slow. Second, the PGS for 
educational attainment is likely associated with many other (non)cognitive traits. Third, 
socio-environmental, cultural and economic factors often override genetic factors for this 
phenotype. Fourth, ‘years of education’ is not a precise measurement and finally, that there 
may be mortality selection in the HRS sample of genotyped individuals, who have a higher 
socioeconomic status.217 
 
10.1 Cohort analysis 
We used the Swedish Twin Register (STR) to examine if the effect of a polygenic score 
(PGS) of AFB and NEB varies across birth cohort. We followed the analysis presented in the 
recent GWAS of education218 and divide the sample into six groups based on their year of 
birth. Each group spans five birth years, with the oldest ranging from 1929-1933 and the 
youngest born between 1954- 1958. We then estimated the following regressions:  
𝐴𝐹𝐵Y = 𝛽/ + 𝛽\𝑃𝐺𝑆wxyY + 𝛽%𝑆𝑒𝑥Y + 𝛾\5𝑐𝑜ℎ𝑜𝑟𝑡5Y05}\ + 𝛾%5𝑃𝐺𝑆wxyY
0
5}\ ×𝑐𝑜ℎ𝑜𝑟𝑡5Y + 𝛽lI5𝑃𝐶lY
\/
l}\ + 𝜀Y 
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𝑁𝐸𝐵Y = 𝛽/ + 𝛽\𝑃𝐺𝑆#yY + 𝛽%𝑆𝑒𝑥Y + 𝛾\5𝑐𝑜ℎ𝑜𝑟𝑡5Y05}\ + 𝛾%5𝑃𝐺𝑆#yY
0
5}\ ×𝑐𝑜ℎ𝑜𝑟𝑡5Y + 𝛽lI5𝑃𝐶lY
\/
l}\ + 𝜀Y 
where 𝑖	 indicate individuals and k	 indexes principal components ( ) of the genetic data. We 
used a PGS standardized to have mean 0 and standard deviation 1 based on the GWAS meta- 
analysis results excluding the STR (details on how we constructed the PGS are available in 
Section 7 of the SI).  The coefficients 𝛾%5 estimate whether there is an interaction between the 
PGS and an individual’s birth cohort.   
 
Supplementary Table 38 reports the estimated coefficient from these regressions. The results 
indicate a U-shaped trend in AFB and a linear decline in NEB, but do not provide any clear 
evidence of interaction effects between the PGS’s and birth cohort. The only interaction 
coefficient that is significantly different from zero is the interaction between the PGS for 
NEB in the most recent birth cohort (those born 1954-1958). This analysis is a first 
descriptive attempt to examine GxE effects with birth cohorts. However, the PGSs are 
weighted by association coefficients of a GWAS where each cohort consists of individuals 
born in different years. Moreover, individual cohorts controlled for linear, quadratic and 
cubic trends in fertility behavior in their analysis. It would be informative to extend these 
analyses to more recent cohorts and contexts and refine the approach.  
10.2 Educational attainment 
We tested the interaction effects between educational level and the PGS of AFB and NEB in 
three different samples (LifeLines, STR and HRS). To ensure out of sample prediction, the 
PGS excluded each respective sample as required.  
For each cohort, we estimated the following regressionsd:  
𝐴𝐹𝐵Y = 𝛽/ + 𝛽\𝑃𝐺𝑆wxyY + 𝛽%𝑆𝑒𝑥Y + 𝛽𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛Y + 𝛽𝑃𝐺𝑆wxyY×𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛Y + 𝛽lI5𝑃𝐶lY\/l}\ + 𝜀Y 
𝑁𝐸𝐵Y = 𝛽/ + 𝛽\𝑃𝐺𝑆#yY + 𝛽%𝑆𝑒𝑥Y + 𝛽𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛Y + 𝛽𝑃𝐺𝑆#yY×𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛Y + 𝛽lI5𝑃𝐶lY\/l}\ + 𝜀Y 
                                                
d For HRS, we estimated only a PGS for NEB, since AFB is not collected in that data. 
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Where educationi is measured as years of education. Supplementary Table 39 reports the 
estimated coefficient from these regressions. The results indicate that years of education are 
positively associated with AFB in both LifeLines and STR, and negatively associated with 
NEB in the HRS. With the exception of NEB in the HRS, we found no evidence of GxE 
effects with education. We can therefore conclude that it appears that education does not 
appear to moderate the effect of the PGS for AFB and NEB. 
 
 11. ROBUSTNESS CHECKS 
To estimate the robustness of our results for AFB, we conducted two additional analyses. 
First, we estimated how the coefficients change if we control for Educational Attainment 
(EA). Using data from deCODE, we ran an additional association analysis using the 10 loci 
that were genome-wide significant in the meta-analysis (p-value<5x10-08). The analysis has 
been restricted to individuals born between 1910 and 1975, who also had data available on 
completed education. The total sample size is 42,187 (17,996 males and 24,191 females). The 
analysis is adjusted for sex, year of birth (linear, squared and cubic), interaction between sex 
and year of birth and the first 10 PCAs. Education is measured by years of education, ranging 
between 10 and 20 years. Supplementary Table 40 reports the association results before and 
after adjusting for educational attainment. Our analysis shows that the effect sizes shrink after 
including educational attainment as a covariate, with an average reduction of around 15%. 
We also estimated the effect of a polygenic risk score of AFB calculated from meta-analysis 
data excluding the deCODE cohort. The polygenic score remains highly significant. The 
effect of 1SD of the AFB score decreases from 0.19 years (69 days) without controlling for 
education to 0.16 years (59 days) when we control for years of education. To summarize, this 
analysis shows that the coefficients are robust to the inclusion of educational attainment in 
the model. 
 
Second, we estimated how the coefficients change after controlling for Education Attainment 
(EA) and Age at First Sex using the UKBiobank (N=50,954). We ran two association 
models: the first follows the GWAS analysis plan with no additional covariates and the 
second added years of education and age at first sexual intercourse as covariates. The results 
are presented in Supplementary Table 41 and Supplementary Figure 37. Our analysis shows 
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that the effect sizes of our top hits are highly concordant (R2=0.94). The inclusion of EA and 
AFS as covariates weakens the effect sizes on average by 40% and increases the p-value of 
the estimated coefficients. However, both EA and AFS have a significant genetic basis and 
are highly genetically correlated with AFB. Therefore, possible genetic pleiotropy may affect 
the results and capture a considerable proportion of the genetic effect. Nevertheless, 7 SNPs 
out of 10 tested, have a p-value<0.05 in the model that controls for EA and AFS. Overall, we 
interpret this additional analysis as a robustness test that confirm that the top hits from our 
meta-analysis are robust to the inclusion of the confounding factors of EA and AFS 
12. POSITIVE SELECTION 
We performed a Haploplotter analysis219 to examine if lead SNPs and/or functional variants 
identified using RegulomeDB show evidence of positive selection. Three variants showed 
standardized integrated haplotype scores <-2 or >2, indicating that these variants represent 
the top 5% of signals in the population. These SNPs are: 1) rs7628058 on chromosome 3 for 
AFB, an eQTLs for RBM6 in monocytes; 2) rs2247510 on chromosome 3 for AFB, an eQTL 
for RBM6 and HYAL3 in monocytes and binding site for a range of transcription factors; 3) 
rs2415984, the lead SNP in the chromosome 14 locus for NEB. Results are presented in 
Supplementary Table 42. 
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The authors thank Birgit Reinhart for her long-term administrative commitment and Ing 
Johann Semmler for the technical assistance at creating the DNA bank.  The research 
reported in this article was funded by the Austrian Science Fond (FWF) grant number 
P20545-P05 and P13180. The Medical University of Graz supports the databank of the 
ASPS. ASPS data can be accessed upon request. 
 
BASEII 
BASE-II was funded by the German Federal Ministry of Education and Research (BMBF) 
and has been formally divided into four subprojects: “Psychology & Project Coordination 
and Database” (Max Planck Institute for Human Development [MPIB], grant number 
16SV5837), “Survey Methods and Social Science” (German Institute for Economic Research 
and Socioeconomic Panel [SOEP/DIW], grant number 16 SV5537), Medicine and Geriatrics 
(Charité – Universitätsmedizin, Berlin [Charité], grant number 16SV5536K), and “Molecular 
Genetics” (Max Planck Institute for Molecular Genetics, now University of Lübeck 
[MPIMG-ULBC], grant number 16SV5538). 
External scientists can apply to the Steering Committee of BASE-II for data access. Although 
the data are available for other parties are scientific data and not personal contact data, the 
scientific data are subject to a security level as if they were personal data to ensure that the 
BASE-II Steering Committee sufficiently protects the large volume of data collected from 
each BASE-II participant. All existing variables are documented in a handbook. Contact: 
Katrin Schaar, scientific coordinator, schaar@mpib-berlin.mpg.de. 
 
BIOS 
The Biobank-based Integrative Omics Study (BIOS) consortium is funded by the Biobanking 
and Biomolecular Research Infrastructure (BBMRI-NL, NWO project 184.021.007). 
 
BMES (Blue Mountains Eye Study) cohort 
The Blue Mountains Eye Study (BMES) was supported by the Australian National Health & 
Medical Research Council (NHMRC), Canberra Australia (NHMRC project grant IDs  
974159, 211069, 302068, and Centre for Clinical Research Excellence in Translational 
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Clinical Research in Eye Diseases, CCRE in TCR-Eye, grant ID 529923).  The BMES 
GWAS and genotyping costs was supported by Australian NHMRC, Canberra Australia 
(NHMRC project grant IDs 512423, 475604 and 529912), and the Wellcome Trust, UK as 
part of Wellcome Trust Case Control Consortium 2 (A Viswanathan, P McGuffin, P 
Mitchell, F Topouzis, P Foster, grant IDs 085475/B/08/Z and 085475/08/Z) 
 
Bruneck Study 
This Bruneck Study is part of the excellence initiative (Competence Centers for Excellent 
Technologies - COMET) of the Austrian Research Promotion Agency FFG: Research Center 
of Excellence in Vascular Ageing - Tyrol, VASCage (K-Project No. 843536) funded by the 
BMVIT, BMWFW, Wirtschaftsagentur Wien and Standortagentur Tirol. There is no public 
access to the Bruneck data base.  
 
CARLA 
This study was funded by a grant from the Deutsche Forschungsgemeinschaft (DFG, German 
Research Foundation) as part of the Collaborative Research Center 598 ‘‘Heart failure in the 
elderly–cellular mechanisms and therapy’’ at the Medical Faculty of the Martin-Luther-
University Halle-Wittenberg; by a grant of the Wilhelm-Roux Programme of the Martin-
Luther-University Halle-Wittenberg; by the Federal Employment Office; and by the Ministry 
of Education and Cultural Affairs of Saxony-Anhalt.  
The study was in accordance with the declaration of Helsinki. All participants gave their 
written informed consent. The study was approved by the local ethic commission of the 
Medical Faculty of the Martin-Luther-University Halle-Wittenberg. 
 
CHAP 
We acknowledge NIH grants R01AG11101 and R01AG030146 for our cohort. 
 
CHS 
Cardiovascular Health Study: This CHS research was supported by NHLBI contracts 
HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, 
N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI 
grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393 
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with additional contribution from the National Institute of Neurological Disorders and Stroke 
(NINDS). Additional support was provided through R01AG023629 from the National 
Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be 
found at CHS-NHLBI.org.  
The provision of genotyping data was supported in part by the National Center for Advancing 
Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and 
Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the 
Southern California Diabetes Endocrinology Research Center.  
The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health.  
 
Cilento Study 
The Cilento study was supported by the Italian Ministry of Education Universities and 
Research (Interomics Flagship Project, PON03PE_00060_7), FP6 (Vasoplus-037254), the 
Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13), and the 
Istituto Banco di Napoli - Fondazione to MC. We address special thanks to the populations of 
Cilento for their participation in the study.  
 
CoLaus 
The CoLaus/PsyCoLaus study was supported by four grants of the Swiss National Science 
Foundation (#105993, 118308, 139468 and 122661), two unrestricted grants from 
GlaxoSmithKline as well as by the Faculty of Biology and Medicine of the University of 
Lausanne. 
 
COPSAC2000  
We greatly acknowledge the private and public research funding allocated to COPSAC and 
listed on www.copsac.com, with special thanks to The Lundbeck Foundation; Danish State 
Budget; Danish Council for Strategic Research; The Danish Council for Independent 
Research and The Capital Region Research Foundation as core supporters. The funding 
agencies did not have any influence on study design, data collection and analysis, decision to 
publish or preparation of the manuscript. No pharmaceutical company was involved in the 
study.  We gratefully express our gratitude to the children and families of the COPSAC2000 
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cohort study for all their support and commitment. We also acknowledge and appreciate the 
unique efforts of the COPSAC research team.  We greatly acknowledge the private and 
public research funding allocated to COPSAC and listed on www.copsac.com, with special 
thanks to The Lundbeck Foundation; Danish State Budget; Danish Council for Strategic 
Research; The Danish Council for Independent Research and The Capital Region Research 
Foundation as core supporters. The funding agencies did not have any influence on study 
design, data collection and analysis, decision to publish or preparation of the manuscript. No 
pharmaceutical company was involved in the study.  We gratefully express our gratitude to 
the children and families of the COPSAC2000 cohort study for all their support and 
commitment. We also acknowledge and appreciate the unique efforts of the COPSAC 
research team, the families participating in the COPSAC cohort for their effort and 
commitment. The authors also thank the COPSAC study team. COPSAC is funded by private 
and public research funds, all of which are listed on the COPSAC website (www.copsac.com; 
see URLs). The Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus 
Foundation, the Danish MRC and The Danish Pediatric Asthma Centre provided core support 
for COPSAC. The funding agencies did not have any role in study design, data collection and 
analysis, the decision to publish or preparation of the manuscript. 
 
CROATIA cohorts 
We would like to acknowledge the invaluable contributions of the recruitment team in 
Korcula, the administrative teams in Croatia and Edinburgh and the people of Korcula. The 
CROATIA-Korcula study was funded by grants from the Medical Research Council (UK), 
European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-
018947), FP7 project BBMRI-LPC (grant 313010), Ministry of Science, Education and 
Sports of the Republic of Croatia (grant 108-1080315-0302) and the Croatian Science 
Foundation (grant 8875). External researchers who wish to obtain access to CROATIA-
Korcula’s data or EA2 results may contact Ozren Polasek, ozren.polasek@mefst.hr. 
 
deCODE 
All deCODE collaborators in this study are employees of deCODE Genetics/Amgen, Inc. 
External researchers who wish to obtain access to data or EA2 results may contact Gudmar 
Thorleifsson gudmar.thorleifsson@decode.is. 
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DESIR 
The D.E.S.I.R. Study Group. INSERM CESP U1018: B. Balkau, M-A. Charles, P. 
Ducimetière, E. Eschwège; INSERM U367: F. Alhenc-Gelas; CHU D'Angers: Y. Gallois, A. 
Girault; Bichat Hospital: F. Fumeron, M. Marre; CHU de Rennes: F. Bonnet; UMR8090, 
LILLE: P. Froguel; Centres d'Examens de Santé: Alençon, Angers, Caen, Chateauroux, 
Cholet, Le Mans, Tours; Institute de Recherche Médecine Générale: J. Cogneau; General 
practitioners of the region; Institute inter-Regional pour la Santé: C. Born, E. Caces, M. 
Cailleau, J.G. Moreau, F. Rakotozafy, J. Tichet, S. Vol. 
The D.E.S.I.R. study has been financed by INSERM contracts with CNAMTS, Lilly, 
Novartis Pharma and Sanofi-Aventis; by INSERM (Réseaux en Santé Publique, Interactions 
entre les déterminants de la santé, Cohortes Santé TGIR 2008), the Association Diabète 
Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, 
ALFEDIAM, ONIVINS, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, 
Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon.  
 
EGCUT 
This study was supported by the Estonian Research Council (grant IUT20-60), the 
Development Fund of the University of Tartu (grant SP1GVARENG), EU structural support 
through Archimedes Foundation, grant no: 3.2.1001.11-0033, EU 7FP grant 278913, and 
H2020 grants 633589, 676550, 654248. Reference:  [PMID: 24518929] Leitsalu et al, Cohort 
Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J 
Epidemiol. 2014 Feb 11 
 
EPIC-Norfolk 
EPIC-Norfolk is  supported  by  programme   grants  from  the  Medical  Research  Council 
(MRC) [G9502233;  G0401527]  and  Cancer  Research  UK  [C864/A8257].  JHZ, KKO and 
NJW are supported by MRC Unit programme grants [MC_UU_12015/1 and 
MC_UU_12015/2]. Further information about the cohort can be found at http://www.epic-
norfolk.org.uk/ 
 
ERF 
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The ERF study as a part of EUROSPAN (European Special Populations Research Network) 
was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-
01947) and also received funding from the European Community's Seventh Framework 
Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European 
Commission under the programme "Quality of Life and Management of the Living 
Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). High-throughput 
analysis of the ERF data was supported by joint grant from Netherlands Organization for 
Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 
047.017.043). Exome sequencing analysis in ERF was supported by the ZonMw grant 
(project 91111025). We are grateful to all study participants and their relatives, general 
practitioners and neurologists for their contributions and to P. Veraart for her help in 
genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help 
in data collection. Najaf Amin is supported by the Netherlands Brain Foundation (project 
number F2013(1)-28). The ERF study genome-wide array data and phenotype data (age and 
gender) is archived in European Genome-Phenome Database (EGA). The study is archived in 
the DAC named Erasmus Rucphen Family Study with the accession code: 
EGAS00001001134. Researchers who wish to use other phenotypic data of the Erasmus 
Rucphen Family Study must seek approval from the management team of the Erasmus 
Rucphen Family study. They are advised to contact the study PI, professor Cornelia van 
Duijn (c.vanduijn@erasmusmc.nl). 
 
Dortmund Health Study DHS 
DHS (Dortmund Health Study) - The collection of sociodemographic and clinical data in the 
Dortmund Health Study was supported by the German Migraine & Headache Society 
(DMKG) and by unrestricted grants of equal share from Almirall, Astra Zeneca, Berlin 
Chemie, Boehringer, Boots Health Care, Glaxo-Smith-Kline, Janssen Cilag, McNeil Pharma, 
MSD Sharp & Dohme and Pfizer to the University of Muenster. Blood collection in the 
Dortmund Health Study was done through funds from the Institute of Epidemiology and 
Social Medicine University of Muenster. Genotyping for the Human Omni Chip was 
supported by the German Ministry of Education and Research (BMBF, grant no. 01ER0816). 
Researchers interested in using DHS data are required to sign and follow the terms of a 
Cooperation Agreement that includes a number of clauses designed to ensure protection of 
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privacy and compliance with relevant laws. For further information, contact Klaus Berger 
(bergerk@uni-muenster.de). 
 
Finnish Twin Cohort 
Phenotype data collection and genotyping in the twin cohort have been supported by  the 
Wellcome Trust Sanger Institute, ENGAGE – European Network for Genetic and Genomic 
Epidemiology, FP7-HEALTH-F4-2007, grant agreement number 201413, Academy of 
Finland (grants 265240, 263278  to JKaprio),  and Global Research Awards for Nicotine 
Dependence (GRAND)  to JK. 
 
FINRISK 
This study was supported by the Academy of Finland Center of Excellence in Complex 
Disease Genetics (grant numbers 213506, 129680), the Academy of Finland (grant numbers 
139635, 129494, 136895, 263836 and 141054), the Sigrid Juselius Foundation , the Paulo 
foundation, the Finnish Medical Foundationand ENGAGE – European Network for Genetic 
and Genomic Epidemiology, FP7-HEALTH-F4-2007, grant agreement number 201413 and  
The Finnish Foundation for Cardiovascular Research. 
 
Generation R 
The Generation R Study is conducted by the Erasmus Medical Center in close collaboration 
with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, 
the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare 
Foundation, Rotterdam and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond 
(STAR-MDC), Rotterdam. We gratefully acknowledge the contribution of children and 
parents, general practitioners, hospitals, midwives and pharmacies in Rotterdam. The study 
protocol was approved by the Medical Ethical Committee of the Erasmus Medical Centre, 
Rotterdam. Written informed consent was obtained from all participants. The general design 
of Generation R Study is made possible by ﬁnancial support from the Erasmus Medical 
Center, Rotterdam, the Erasmus University Rotterdam, the Netherlands Organization for 
Health Research and Development (ZonMw), the Netherlands Organisation for Scientific 
Research (NWO), the Ministry of Health, Welfare and Sport and the Ministry of Youth and 
Families.  Vincent W. Jaddoe received an additional grant from the Netherlands Organization 
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for Health Research and Development (VIDI 016.136.361) and a European Research Council 
Consolidator Grant (ERC-2014-CoG-648916). The generation and management of GWAS 
genotype data for the Generation R Study were done at the Genetic Laboratory of the 
Department of Internal Medicine, Erasmus MC, the Netherlands. We would like to thank 
Karol Estrada, Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and Rob de Graaf, 
for their help in creating GRIMP, BigGRID, MediGRID, and Services@MediGRID/D-Grid, 
(funded by the German Bundesministerium fuer Forschung und Technology; grants 01 AK 
803 A-H, 01 IG 07015 G) for access to their grid computing resources. We thank Mila 
Jhamai, Manoushka Ganesh, Pascal Arp, Marijn Verkerk, Lizbeth Herrera and Marjolein 
Peters for his help in creating, managing and QC of the GWAS database. Also, we thank 
Karol Estrada for their support in creation and analysis of imputed data. J.F.F. has received 
funding from the European Union's Horizon 2020 research and innovation programme under 
grant agreement No 633595 (DynaHEALTH). 
 
GENOA  
GENOA (Genetic Epidemiology Network of Arteriopathy): Support for GENOA was 
provided by the National Heart, Lung and Blood Institute (HL119443, HL118305, 
HL054464, HL054457, HL054481, HL071917 and HL87660) of the National Institutes of 
Health. Genotyping was performed at the Mayo Clinic (Stephen T. Turner, MD, Mariza de 
Andrade PhD, Julie Cunningham, PhD). We thank Eric Boerwinkle, PhD and Megan L. 
Grove from the Human Genetics Center and Institute of Molecular Medicine and Division of 
Epidemiology, University of Texas Health Science Center, Houston, Texas, USA for their 
help with genotyping. We would also like to thank the families that participated in the 
GENOA study. Data Access: GENOA (Genetic Epidemiology Network of Arteriopathy): In 
accordance with the informed consents of the GENOA study, we provide individual-level 
genotype and phenotype data to GENOA investigators and collaborators. To collaborate with 
GENOA investigators, please contact Sharon L.R. Kardia (skardia@umich.edu). We fully 
welcome collaboration with researchers that would like to include the GENOA sample in 
their analyses. We can allow transfer of individual-level data with an appropriate Data 
Transfer Agreement.   
 
GOYA  
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The Danish National Research Foundation established the Danish Epidemiology Science 
Centre, which initiated and created the Danish National Birth Cohort. The cohort is a result of 
a major grant from this Foundation. Additional support for the Danish National Birth Cohort 
was obtained from the Pharmacy Foundation, the Egmont Foundation, the March of Dimes 
Birth Defects Foundation, and the Augustinus Foundation. Genotyping for the GOYA Study 
within the Danish National Birth Cohort was funded by the Wellcome Trust (Grant ref: 
084762MA). 
 
HBCS 
We thank all study participants as well as everybody involved in the Helsinki Birth Cohort 
Study. Helsinki Birth Cohort Study has been supported by grants from the Academy of 
Finland, the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo 
Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg 
Foundation,University of Helsinki, Ministry of Education, Ahokas Foundation, Emil 
Aaltonen Foundation. 
 
Health 2000 
The Health 2000 Study was mainly funded from the budget of the National Institute for 
Health and Welfare (THL). Additional funding was received from the Finnish Centre for 
Pensions, the Social Insurance Institution of Finland, the Local Government Pensions 
Institution, the National Research and Development Centre for Welfare and Health, the 
Finnish Dental Association, the Finnish Dental Society, Statistics Finland, the Finnish 
Institute for Occupational Health, The Finnish Work Environment Fund, the UKK Institute 
for Health Promotion Research and the Occupational Safety and Health Fund of the State 
Sector. The data used for this study can be made available on request to the Health 2000/2011 
scientific committee according to the ethical and research guidelines 
(www.terveys2011.info/aineisto) as well as Finnish legislation.  
 
Health ABC 
The Health ABC Study was supported by NIA contracts N01AG62101, N01AG62103, and 
N01AG62106 and, in part, by the NIA Intramural Research Program. The genome-wide 
association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University 
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Health Sciences and genotyping services were provided by the Center for Inherited Disease 
Research (CIDR). CIDR is fully funded through a federal contract from the National 
Institutes of Health to The Johns Hopkins University, contract number 
HHSN268200782096C. This study utilized the high-performance computational capabilities 
of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. 
(http://biowulf.nih.gov). 
 
HRS 
HRS (Health and Retirement Study): HRS is supported by the National Institute on Aging 
(NIA U01AG009740).  The genotyping was funded separately by the National Institute on 
Aging (RC2 AG036495, RC4 AG039029).  Our genotyping was conducted by the NIH 
Center for Inherited Disease Research (CIDR) at Johns Hopkins University.  Genotyping 
quality control and final preparation of the data were performed by the Genetics Coordinating 
Center at the University of Washington. Data Access: 
HRS (Health and Retirement Study): Genotype data can be accessed via the database of 
Genotypes and Phenotypes (dbGaP, http://www.ncbi.nlm.nih.gov/gap, accession number 
phs000428.v1.p1). Researchers who wish to link genetic data with other HRS measures that 
are not in dbGaP, such as fertility data, must apply for access from HRS.  See the HRS 
website (http://hrsonline.isr.umich.edu/gwas) for details. 
HTO 
We thank all the families who contributed to this study.  Phenotyping and genotyping of the 
HTO cohort was funded by the Wellcome Trust, the UK Medical Research Council and the 
British Heart Foundation.  Data are available upon request from the Principal Investigator, 
Bernard Keavney (bernard.keavney@manchester.ac.uk). 
 
INGI-CARL  
We thank Martina La Bianca and Angela D’Eustacchio for technical support. We are very 
grateful to the municipal administrators for their collaboration on the project and for logistic 
support. We would like to thank all participants to this study.  
 
INGI-Val Borbera 
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We thank all the participants to the project, the San Raffaele Hospital MDs who contributed 
to clinical data collection,  prof. Clara Camaschella  who coordinated  the data collection, 
Corrado Masciullo and Massimiliano Cocca for the  database informatics. 
The research was supported by funds from Compagnia di San Paolo, Torino, Italy; 
Fondazione Cariplo, Italy; Telethon Italy; Ministry of Health, Ricerca Finalizzata 2008 and 
2011-2012 and Public Health Genomics Project 2010. 
 
KORA F3 
The KORA study was initiated and financed by the Helmholtz Zentrum München – German 
Research Center for Environmental Health, which is funded by the German Federal Ministry 
of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA 
research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-
Maximilians-Universität, as part of LMUinnovativ. 
The funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. We thank all the study participants, all members of staff of the 
Institute of Epidemiology II and the field staff in Augsburg who planned and conducted the 
study. 
 
LBC1921 and LBC1936 
We thank the cohort participants and team members who contributed to these studies. 
Phenotype collection in the Lothian Birth Cohort 1921 was supported by the UK’s 
Biotechnology and Biological Sciences Research Council (BBSRC), The Royal Society, and 
The Chief Scientist Office of the Scottish Government. Phenotype collection in the Lothian 
Birth Cohort 1936 was supported by Age UK (The Disconnected Mind project).  Genotyping 
of the cohorts was funded by the BBSRC. The work was undertaken by The University of 
Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross 
council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the 
BBSRC and Medical Research Council (MRC) is gratefully acknowledged. 
 
LIFELINES 
Lifelines is a multi-disciplinary prospective population-based cohort study examining in a 
unique three-generation design the health and health-related behaviors of 167,729 persons 
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living in the North of The Netherlands. It employs a broad range of investigative procedures 
in assessing the biomedical, socio-demographic, behavioral, physical and psychological 
factors which contribute to the health and disease of the general population, with a special 
focus on multi-morbidity and complex genetics.220,221 
The Lifelines Cohort Study, and generation and management of GWAS genotype data for the 
Lifelines Cohort Study is supported by the Netherlands Organization of Scientific Research 
NWO (grant 175.010.2007.006), the Ministry of Economic Affairs, the Ministry of 
Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern 
Netherlands Collaboration of Provinces (SNN),  the Province of Groningen, University 
Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation and 
Dutch Diabetes Research Foundation. The authors wish to acknowledge the services of the 
Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all 
the study participant. Data availability: Lifelines is a facility that is open for all researchers. 
Information on application and data access procedure is summarized on www.lifelines.net. 
 
Longevity 
National Institutes of Health (AG028872, CA164468 and DA033788  to A.B., AG042188 to 
G.A., AG021654-01 and AG-18728-02A1 to N.B.) and the Glenn Center for the Biology of 
Human Aging. 
 
MCTFR 
MCTFR acknowledges support by the National Institutes of Health under award numbers 
R37DA005147, R01AA009367, R01AA011886, R01DA013240, and R01MH066140.  
 
MESA 
MESA and the MESA SHARe project are conducted and supported by the National Heart, 
Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for 
MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, 
N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-
HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-001079, UL1-TR-
000040, and DK063491. Funding for SHARe genotyping was provided by NHLBI Contract 
N02-HL-64278.  Genotyping was performed at Affymetrix  (Santa Clara, California, USA) 
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and the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) using the 
Affymetrix Genome-Wide Human SNP Array 6.0. 
  
MoBa 
MoBa (The Norwegian Mother and Child Cohort Study of NIPH) – the genotyping and 
analyses were supported by the grants from: Jane and Dan Olsson Foundations (Gothenburg, 
Sweden), Swedish Medical Research Council (2015-02559), Norwegian Research 
Council/FUGE (grant no. 151918/S10; FRI-MEDBIO 249779) and Swedish Medical Society 
(SLS 2008-21198), Swedish government grants to researchers in the public health service 
(ALFGBG-507701).  
The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of 
Health and Care Services and the Ministry of Education and Research, NIH/NIEHS (contract 
no N01-ES-75558), NIH/NINDS (grant no.1 UO1 NS 047537-01 and grant no.2 UO1 NS 
047537-06A1). We are grateful to all the participating families in Norway who take part in 
this on-going cohort study. 
 
MrOS Sweden 
MrOS Sweden was funded by the Swedish Research Council, the Swedish Foundation for 
Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, 
the Torsten and Ragnar Söderberg's Foundation and the Novo Nordisk Foundation. 
 
NEO 
The authors of the NEO study thank all individuals who participated in the Netherlands 
Epidemiology in Obesity study, all participating general practitioners for inviting eligible 
participants and all research nurses for collection of the data. We thank the NEO study group, 
Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data 
management of the NEO study. The genotyping in the NEO study was supported by the 
Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO 
study is supported by the participating Departments, the Division and the Board of Directors 
of the Leiden University Medical Center, and by the Leiden University, Research Profile 
Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch 
Science Organization (ZonMW-VENI Grant 916.14.023).  
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NESDA 
The infrastructure for the NESDA study is funded through the Geestkracht programme of the 
Dutch Scientific Organization (ZON-MW, grant number 10-000-1002) and matching funds 
from participating universities and mental health care organizations. Genotyping in NESDA 
was funded by the Genetic Association Information Network (GAIN) of the Foundation for 
the US National Institutes of Health. Statistical analyses were carried out on the Genetic 
Cluster Computer (http://www.geneticcluster.org), which is financially supported by the 
Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the 
Dutch Brain Foundation. 
Data availability 
Data are available upon request from the NESDA data management bureau. 
 
Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) 
Supported by grants UM1 CA186107, UM1 CA167552, DK091718, HL071981, HL073168, 
CA87969, CA49449, CA055075, HL34594, HL088521, U01HG004399, DK080140, 
5P30DK46200, U54CA155626, DK58845, U01HG004728-02, EY015473, DK70756 and 
DK46200 from the National Institutes of Health, with additional support for genotyping from 
Merck Research Laboratories, North Wales, PA.  
 
NTR (Netherlands Twin Register) 
Netherland Twin Register: Funding was obtained from the Netherlands Organization for 
Scientific Research (NWO) and The Netherlands Organisation for Health Research and 
Development (ZonMW) grants 904-61-090, 985-10-002, 904-61-193,480-04-004, 400-05-
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